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Summary 
Glioblastoma multiforme (GBM) (WHO classification IV) is the most common primary 
malignant brain tumor with a poor prognosis in both adults and children. In the last years 
several studies have shown that 44% of glioblastoma multiforme tumors are characterized 
by the same histone mutations manifested in the histone variant H3.3. These studies 
strongly implicate the K27M amino acid substitution in H3.3 in the pathogenesis of diffuse 
intrinsic pontine glioma (DIPG). Also, H3.3 has been recently linked to multiple processes in 
the brain like neuronal specialization, synapses, cognition and contextual fear memory. 
In this study, two important tools were generated to investigate the role of H3.3 in the brain. 
Firstly, making use of the RCAS/TVA system, we established a DIPG mouse model 
overexpressing constitutively active AKT, PDGFB, Luciferase and floxed H3.3K27M in Nestin 
expressing cells in the brain. This model resembles High Grade Gliomas (HGGs) in histology 
and shows a key feature observed in the human DIPG tumors that is the H3K27me3 loss. In 
combination with Bioluminescence Imaging (BLI), the model enables monitoring of tumor 
growth. The model allowed for H3K27me3 recovery after deletion of H3.3K27M. 
Secondly, we successfully established an inducible RFP-tagged H3f3b-overexpressing mouse 
line. By modifying a Bacterial Artificial Chromosome (BAC) carrying the H3f3b gene, the 
fusion protein H3f3b-RFP-ERT2 was overexpressed. This construct allows for histone tracing 
in living behaving animals. 
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Zusammenfassung 
Glioblastoma multiforme (GBM) (WHO Klasse IV) ist der häufigste primäre bösartige 
Gehirntumor, mit einer schlechten Prognose sowohl für Erwachsene wie auch für Kinder. 
Verschiedene Studien der letzten Jahre haben gezeigt, dass 44% der GBM Tumore durch 
bestimmte Mutationen in der Histonvariante H3.3 charakterisiert sind. Diese Studien deuten 
stark darauf hin, dass im diffus intrinsisichen Ponsgliom (DIPG) ein K27M 
Aminosäurenaustausch in H3.3 stattfand. Des Weiteren wurde H3.3 mit vielen anderen 
Prozessen in Verbindung gebracht, wie neuronale Spezialisierung im Gehirn, Synapsen, 
kognitives und kontextuelles Angstgedächtnis. 
In der hier vorliegenden Arbeit wurden zwei wichtige Methoden entwickelt um die Rolle von 
H3.3 im Gehirn zu analysieren. Als erstes wurde das RCAS/TVA System benutzt um ein 
Mausmodel für DIPG, durch Überexpressison von konstitutiv aktivem AKT, PDGFRB, 
Luciferase und gefloxtem H3.3K27M in Nestin exprimierenden Zellen im Mausgehirn, 
entwickelt. Diese Modell hat eine ähnliche Histologie wie hochgradige Gliomas (HGGs) und 
zeigt ein Kennzeichen welches in humanen DIPG Tumoren beobachtet wurde, den Verlust 
von H3K27me3. In Verbindung mit bioluniniszenter Bildgebung kann mit diesem Modell der 
Tumorwachstum beobachtet werden. Nach der Deletion von H3.3K27M konnte H3K27me3 
wieder detektiert werden. 
 Zweitens, wurde erfolgreich eine neue Mauslinie etabliert, in welcher die Expression von 
RFP-getaggtem H3f3b induziert werden konnte. Dies wurde dur die Modifizierung eines 
bakteriellen artifiziellen Chromosomes (BAC) mit dem H3f3b Gen erreicht, so dass das 
Fusionsprotein H3f3b-RFP-ERT2 überexprimiert wurde. Mit diesem Konstrukt ist es möglich 
Histone in lebendigen Zellen und Tieren zu verfolgen.
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1. Introduction 
1.1. Brain tumors 
Glioblastoma multiforme (GBM) shows a low incidence when compared with the most 
common cancers like lung cancer, breast cancer, colorectal cancer, prostate cancer, stomach 
cancer and liver cancer. GBM incidence was around 1-2% in 2012 while the six types of 
cancer mentioned before accounted for 55% of global cases (Ferlay et al., 2015). However, 
GBM is one of the most common primary malignant brain tumors, with poor prognosis in 
both adult and children(Ostrom et al., 2014). The overall survival for patients diagnosed with 
Glioblastoma is 1-2 years (Grossman et al., 2010).  
1.1.1. WHO classification 
The World Health Organization (WHO) classifies gliomas according to the analysis of 
differentiation, cell density, nuclear atypia, mitotic activity, microvascular proliferation and 
necrosis (Ricard et al., 2012) as grade 2 (diffuse infiltrating low-grade gliomas), 3 (anaplastic 
gliomas), or 4 (glioblastomas) with increasing aggressiveness (Table 1.1). GBMs that arise 
from diffuse astrocytoma (WHO grade II) or anaplastic astrocytoma (WHO grade III) are 
called secondary GBM (5% of the cases), while de novo GBMs (primary GBMs) comprise the 
remaining 95%(Ohgaki and Kleihues, 2007). 
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Table 1.1. Histological classification of diffuse gliomas and overall survival. Reproduced with permission from (Ricard et al., 2012) 
1.1.2. Paediatric glioblastoma 
Brain tumors represent 20% of all cancer cases in children(Hargrave et al., 2006), and are the 
first cancer-related cause of death in children(Stiller, 1994). These tumors have a wide 
variety both histologically and anatomically. One the most diverse brain tumor groups are 
gliomas; they originate from any place in the Central Nervous System (CNS) and present 
different histology. Within the gliomas that are located in the brain stem 20% of them 
comprise low-grade astrocytomas while the remaining 80% arise from the pons and present 
a diffuse histology(Hargrave et al., 2006). Diffuse intrinsic pontine glioma (DIPG) represents 
one of the paediatric brain tumors with the worst prognosis; most studies have a median 
survival of less than one year. Diagnosis nowadays is based on MRI and clinical findings while 
tissue biopsies are not recommended. 
1.1.3. Histology and Pathology 
DIPGs are originated in the brain stem and due to the diffusive and infiltrative nature in 
combination with the location surgical resection is usually not an option (Maria et al., 1993). 
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Despite all the advances in medicine DIPG treatment has not significantly improved in the 
last decades. Radiation is the standard of care for the patients but only offers palliative 
results while chemotherapy has not shown results so far (Hargrave et al., 2006). One 
probable cause for the failure of treatment improvement is the adaptation of techniques 
used for adult glioblastoma (Donaldson et al., 2006). 
1.2. Chromatin 
The length of the DNA molecule in the cell requires it to be packaged in order to fit inside the 
nucleus. Histones are the proteins in charge of that task and at the same time, they enable 
the cellular machinery to access the DNA in processes like transcription, recombination, DNA 
repair and replication. The combination of DNA and all associated proteins is named 
chromatin. Histone proteins interact with each other and with the DNA to form the basic 
unit of the chromatin which is the nucleosome. The histone H3 and H4 are combined in a 
tetramer (H3-H4)2 and with the addition of two dimers of H2A-H2B they compose the 
nucleosome. Approximately two turns of the DNA helix (147 base pairs) are wrapped around 
a nucleosome providing both the necessary packaging and the protection. Despite the 
primary function as architectural proteins, histones are involved in several cellular processes 
as DNA repair and chromosome segregation. Chromatin regulation at the level of histones is 
made mainly by two means: post-transcriptional modifications (PTMs) and the incorporation 
of histone variants into the nucleosome. PTMs occur preferentially in the histone tail that 
hangs out of the core of the nucleosome. These modifications include acetylation, 
methylation, phosphorylation and ubiquitination (Kouzarides, 2007). These PTMs have 
strong implications for the regulation of transcription and DNA replication and also for the 
maintenance of the genome stability. 
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1.2.1. Histone H3.3 
In mammalians there are several histone H3 variants. Histones H3.1 and H3.2 are referred to 
as canonical histone H3 and only differ by one amino acid from each other while there are 
four additional replacement histones: centromere specific variant CENP-A, H3.3 (Szenker et 
al., 2011) and testis-specific histones H3.4 (also known as H3t)(Witt et al., 1996) and H3.5 
(also known as H3.3C)(Schenk et al., 2011). The primate-specific H3 variants, H3.X and H3.Y 
can also be added to that list (Wiedemann et al., 2010). Comparing the histone variant H3.3 
with its canonical counterpart we can observe differences arising from several levels (Figure 
1.1).  
 
 
 
 
 
 
 
 
 
 
Figure 1.1. Differences between the canonical H3 variants and the histone variant H3.3. Reproduced with permission from (Szenker et 
al., 2011). 
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First, in terms of genomic organization the canonical histones H3 are encoded by multiple 
genes, which cluster together in the genome. The genes encoding the canonical histones H3 
don’t have introns and their resultant mRNAs are not polyadenylated. Also their translation 
is highly regulated by the binding of the stem loop binding protein and of the U7 small 
nuclear RNA to the 3′ end of the histone RNAs (Marzluff et al., 2002). These particular 
genomic and transcriptional characteristics allow a rapid production from the histone H3 
canonical genes during the S phase to provide the cell with the necessary pool of H3 protein 
needed during replication in a DNA synthesis-coupled (DSC) manner. One exception to this is 
the canonical histone H3.1 which can be incorporated outside of the S phase in the event of 
DNA repair after UV lesion (Polo et al., 2006). In contrast, the histone variant H3.3 is 
encoded by only two genes. H3.3A and H3.3B are located in different chromosomes, they 
have different DNA sequences and regulatory regions but the encoding proteins have exactly 
the same amino acid sequence (Akhmanova et al., 1995; Frank et al., 2003; Krimer et al., 
1993). Opposite to the canonical histone H3, histone H3.3 genes possess introns and the 
transcribed mRNAs are polyadenylated. Second, histone variant H3.3 can be incorporated 
into the nucleosomes throughout the whole cell cycle both in a DSC and DSI (DNA synthesis-
independent) manner. H3.3 differs in only 4 amino acid differences from H3.2 (at positions 
31, 87, 89 and 90) and in five from H3.1 (an additional difference at position 96). Due to the 
high sequence similarity between H3.3 and the equivalent canonical H3 these particular 
amino acid differences have been proposed to be responsible for H3.3 distinct 
characteristics. Residues 87, 89 and 90 are especially interesting in terms of the DSI 
deposition of H3.3. These three residues are shared among vertebrates and Drosophila been 
Serine, Valine and Methionine for H3 and Alanine, Isoleucine and Glycine for H3.3. Direct 
mutagenesis of these amino acid residues in Drosophila H3 to the corresponding H3.3 
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residues achieved DSI deposition of H3 (Ahmad and Henikoff, 2002). This finding supports 
the idea that the pattern SVM (Serine, Valine and Methionine) in H3 is responsible for its 
restricted deposition. In addition, mutation of the sequence of H3.3B gene to the canonical 
H3.2 in mouse embryonic stem (ES) cells alters the genome-wide distribution of H3.3 
showing that this particular sequence determines its distribution (Goldberg et al., 2010).  
1.2.2. Histone H3.3 deposition 
Canonical H3 is incorporated into chromatin strictly during S phase in a DSC manner. This 
process is mediated by two chaperones: antisilencing function protein 1 (ASF1) and 
chromatin assembly factor-1 (CAF-1) and results in a non-specific and broad genomic 
distribution. Variant H3.3, which exhibits a DSI deposition, uses two different deposition 
pathways for the incorporation into the chromatin. The first one is mediated by the histone 
regulator A (HIRA) complex and targets H3.3 to transcriptionally active genic regions. The 
second one, death-domain-associated protein/α-thalassemia and mental retardation 
syndrome X-linked protein (DAXX/ATRX) complex mediates the deposition of H3.3 to 
pericentromeric, telomeric and repeat regions of the genome (Elsasser et al., 2015; Goldberg 
et al., 2010; Ray-Gallet et al., 2011). The specific change in residue 90, methionine in the 
canonical H3 and glycine in the H3.3 variant, allows the formation of a hydrogen bond 
between H3.3 and DAXX. The point mutation of this residue to glycine but not to alanine 
permits H3.2 recognition by DAXX (Elsasser et al., 2012). This example shows how important 
one amino acid can be for the interaction with different chaperone complexes. 
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1.2.3. Lysine 27 methylation 
Whenever both canonical and variant histone H3 are incorporated into the nucleosome the 
amino terminal end of the protein stays out of the nucleosome core as a tail. This specific 
disposition of the H3 tail makes it the target of different PTMs affecting the complex 
regulation of H3 (Figure 1.2).  
Figure 1.2. Post-translational modifications of the H3.3 tail and multiple alignment of a region of the tail showing the conservation from 
plants to mammals. Reproduced with permission from (Schwartzentruber et al., 2012) 
K27me3 is a PTM associated with transcriptional repression; furthermore enrichment of 
H3K27me3 correlates with gene silencing (Barski et al., 2007). In addition, results showed 
that H3K27me3 and the transcription elongation mark H3K36me3 have distinct localizations 
(Mikkelsen et al., 2007). The methylation of the histone 3 lysine 27 is a process catalyzed by 
the Polycomb repressive complex 2 (PRC2). The core PCR2 complex is composed by four 
subunits: EZH1/2, SUZ12, EED and RbAp46/48 and is conserved from Drosophila to 
mammals. PRC2’s normal function is to maintain epigenetic gene silencing and X 
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chromosome inactivation through enzymatic di and trimethylation of the Lysine 27 of the 
histone H3 (Margueron and Reinberg, 2011).  
Additionally to its four subunits PRC2 interacts with AEBP2, PCLs and JARID2. AEBP2 is a zinc-
finger protein that interacts with PRC2 to enhance its enzymatic activity (Cao and Zhang, 
2004). PCLs (PCL1, PCL2 and PCL3) are the three mammalian orthologues of Drosophila PCL. 
They share the same protein motifs: a tudor domain, two plant homeodomain (PHD) finger 
domains, a PCL extended domain and a carboxy-terminal domain tail (Wang et al., 2004). 
PCLs regulate PRC2 enzymatic activity (Nekrasov et al., 2007; Sarma et al., 2008) and gene 
recruitment of PRC2 (Savla et al., 2008; Walker et al., 2010). JARID2 is a member of the 
Jumonji family of proteins that catalyzes the demethylation of histone proteins. JARID2 has 
some conserved regions in its carboxy-terminal end like the ARID domain (potentially a DNA-
binding domain), the JmjC and JmjN domains, and a zinc-finger domain. Genome-wide 
studies have shown that JARID2 is an inhibitor of PRC2 enzymatic activity (Peng et al., 2009; 
Shen et al., 2009). Different studies on these three additional components of the PRC2 
complex have shown that they are not strictly necessary for PRC2 enzymatic activity in vitro, 
however there are required for an optimal activity. 
1.2.4. H3.3 function  
H3.3 is found across the genome in open chromatin associated with actively transcribed 
genes and in regions more inactive like telomeres and pericentric chromatin (Shi et al., 
2016). This specific genomic distribution supports a role for H3.3 in gene activation and 
silencing in a context-dependent manner. 
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1.2.4.1. H3.3 function in chromatin dynamics and transcriptional regulation 
The high homology between histone variant H3.3 and the canonical histones H3 makes it 
unlikely that the incorporation of H3.3 into the nucleosome would affect its stability or 
structure (Chen et al., 2013; Thakar et al., 2009). Incorporation of H3.3 into the nucleosome 
regulates chromatin folding causing an open chromatin conformation (Chen et al., 2013). 
H3.3 counteracts the incorporation of the histone linker H1 altering chromatin compaction 
as a result. H3.3-enriched regions in Drosophila cells have low levels of H1 and upon 
knockdown of H3.3 these regions increase the levels of H1 (Braunschweig et al., 2009). H3.3 
keeps the balance between open and closed chromatin, which is critical for mouse 
preimplantation development. Loss of H3.3 causes over-condensation and mis-segregation 
of chromosomes in the two-cell stage leading to aneuploidy (Torres-Padilla et al., 2006). As 
mentioned before the incorporation of the histone variants H3.3 or H2A.Z does not affect 
the structure of the nucleosome (Chen et al., 2013; Suto et al., 2000), however nucleosomes 
containing these two histone variants seem less stable than those containing the canonical 
versions H3 and H2A (Jin and Felsenfeld, 2007). The instability of these nucleosomes makes 
them prone to disassembly and facilitates the access of transcription factors and other 
chromatin-associated factors to the chromatin in human cells (Jin et al., 2009). H3.3 is a 
mark of transcriptionally activated genes being enriched at promoters, gene bodies and cis-
regulatory elements. At dynamic regions H3.3 distribution is conserved from yeast to 
humans (Dion et al., 2007; Ray-Gallet et al., 2011; Rufiange et al., 2007; Schneiderman et al., 
2012; Shu et al., 2014; Stroud et al., 2012; Wollmann et al., 2012). Loss of H3.3 genes in 
Drosophila leads to genes both upregulated and downregulated due to transcriptional 
impairment. Results showed that the genes that were downregulated were mainly highly 
transcribed genes supporting that H3.3 is required for the transcription of active genes. 
                                                                                                                                                                Introduction 
 
20 
 
Furthermore, H3.3 turnover in promoters and coding regions correlates with polymerase 
density and transcription level (Jin et al., 2009; Kraushaar et al., 2013). The presence of H3.3 
at the promoter region is not limited to active genes; H3.3 can be also found in the 
promoters of inactive genes probably due to being in a poised state or as reminiscence of 
previous activation (Mito et al., 2005; Tamura et al., 2009). H3.3 is necessary for the 
establishment of H3K27me3 at the promoters of developmentally regulated genes in mouse 
ES cells. H3.3 knockdown results in reduced PRC2 occupancy and H3K27me3 levels but the 
chromatin landscape of actively transcribed regions like the ones marked with H3K4me3 is 
not changed (Banaszynski et al., 2013). Despite its association with actively transcribed 
regions H3.3 has been shown to be incorporated into inactive regions such as telomeres, 
pericentric chromatin and silent retroviral elements (Drane et al., 2010; Goldberg et al., 
2010; Lewis et al., 2010). Altogether, these results point at a complex regulation mechanism 
of activation and repression of gene expression and of chromatin conformation by H3.3 in a 
context-dependent manner. 
1.2.4.2. H3.3 function during development 
H3.3 is a highly conserved histone variant among different species which points at the 
possibility of it having a conserved function as well. Knockout of both genes, H3.3A and 
H3.3B, in flies causes complete sterility, transcriptional defects of highly transcribed genes 
and partial lethality (Sakai et al., 2009). H3.3-deficient flies were affected in the expression 
of a subset of genes in adults but the timed and localized expression of key developmental 
genes was not affected (Hodl and Basler, 2009). Knockout models of either H3.3A or H3.3B 
have shown the importance of H3.3 expression during development. H3.3A knockout mice 
were viable to adulthood, however males were found to be subfertiles, while H3.3B 
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homozygous knockout mice showed deficient embryonal growth and did not survive birth. 
H3.3B heterozygous knockout mice were infertile (Tang et al., 2015). Also, H3.3B knockout in 
Mouse Embryonic Fibroblast (MEF) cells resulted in karyotype abnormalities, ectopic CENP-A 
localization and defective chromosome segregation signifying the importance of H3.3 for 
maintaining chromosome integrity. 
H3.3 expression peaks at gastrulation during Xenopus development and in the case of a 
reduction of H3.3 levels gastrulation is arrested and abnormal expression of late mesoderm 
markers is observed (Ng and Gurdon, 2008). Knockdown of H3.3 in fertilized mouse zygotes 
produces growth arrest at the morula stage (Lin et al., 2013). H3.3-deficient embryos show a 
close chromatin phenotype with reduced levels of H3K36me2 and H4K16Ac (open chromatin 
markers) and increased incorporation of histone linker H1, which results in over-
condensation and mis-segregation of the chromosomes (Lin et al., 2013). These results 
support the hypothesis of H3.3 being in charge of balancing between an open and close 
chromatin state during early development. Furthermore, the knockout phenotype of HIRA in 
mice is similar to the observed phenotype in H3.3-deficient Xenopus embryos  with 
embryonic lethality and defects in early gastrulation (Roberts et al., 2002; Szenker et al., 
2012). DAXX and ATRX knockout mice result in lethality before E9.5 (Garrick et al., 2006; 
Michaelson et al., 1999). Therefore, HIRA, DAXX and ATRX are essential for early embryonic 
development but whether this is specifically linked to H3.3 remains to be proven.  
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1.2.4.3. H3.3 function in cell differentiation 
Pluripotent ES cells have the ability to differentiate into multiple lineages as well as self-
renewal capacity. This differentiation potential is maintained in ES cells by marking specific 
genes important for the differentiation into a particular lineage before their expression is 
induced. In ES cells, the promoters of these lineage-specific genes are marked with H3K4me3 
and H3K27me3 modifications. The H3K4me3 mark is usually associated with gene activation 
while the H3K27me3 mark is associated with gene repression. These regions marked with 
H3K4me3 and H3K27me3 are called bivalent domains. Results from mouse ES cells show that 
H3.3 is enriched in these domains (Goldberg et al., 2010). Upon differentiation to neuronal 
precursor cells (NPCs) the genome-wide distribution of H3.3 changes. Now, those bivalent 
genes that were activated in NPCs present H3.3 at the transcription starting site (TSS) and 
the gene body. Opposite to that, bivalent genes that were repressed showed decreased H3.3 
at the TSS (Goldberg et al., 2010). In addition, upon knockdown of H3.3 in ES cells the 
expression patterns of bivalent genes was changed during the differentiation process (Xiong 
et al., 2016). These findings suggest an essential role for H3.3 in ES cell differentiation, which 
will need further study to be unraveled. 
1.2.4.4. H3.3 function in the brain 
Given the fact that histone H3.3 can be deposited throughout the whole cell cycle it is logical 
to raise the question if H3.3 would function in the same way in post-replicative cells like 
neurons as it is in dividing cells. Furthermore, the role of H3.3 in transcriptional regulation 
points at the importance of H3.3 in the developmental brain and in neuronal specialization. 
Neuronal specialization and plasticity are mediated by activity-dependent changes in gene 
expression (Greer and Greenberg, 2008). Activity-dependent gene expression can be 
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regulated by manipulation of the chromatin structure to control the accessibility of the 
transcriptional machinery to the DNA but the mechanism used to achieve this remains 
unclear (Borrelli et al., 2008; Maze et al., 2013). Nucleosomal histones have been classically 
considered highly stable proteins with a slow turnover and half-lives from months to years in 
post-replicative cells (Commerford et al., 1982). Due to that, former studies in the CNS 
focused on PTMs and chromatin remodeling as the causes of transcriptional and behavioral 
plasticity. However, recent results in budding yeast and Drosophila showed rapid 
incorporation of histone variants within active regions of the genome (Deal et al., 2010; Dion 
et al., 2007) suggesting that rapid nucleosome turnover could affect gene expression in 
mammalian brain. Classical (Commerford et al., 1982) and recent (Savas et al., 2012; Toyama 
et al., 2013) analysis of protein stability in rat brain showed a long half-live for H3 over the 
lifetime of the animal. In addition, studies indicated that H3.3 is accumulated in the brain 
with age, reaching levels of over 90% of the total H3 pool while canonical H3 levels 
decreased (Maze et al., 2015; Pina and Suau, 1987)(Figure 1.3). These findings point at a 
different mechanism of chromatin regulation in neurons due to the enrichment of H3.3. 
Also, different studies support a role for nucleosome dynamics during activity-dependent 
transcriptional responses in the brain (Maze et al., 2015; Michod et al., 2012; Sun et al., 
2015; Zovkic et al., 2014). Specifically, nucleosome turnover has been shown to be necessary 
for neuronal and glial specific gene expression, synaptic connectivity, dendritic spine 
formation and maintenance and cognition. H3.3 is incorporated into the nucleosomes by 
HIRA and removed in a proteasomal-dependent manner which promotes cell-type specific 
transcriptional responses. Additionally, reduction of H3.3 turnover in neurons impairs the 
transcription of activity-dependent synaptic genes, reduces dendritic spines, decreases 
excitatory (glutamatergic) and inhibitory (GABAergic) synapses, and impairs cognition (Maze 
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et al., 2015; Wenderski and Maze, 2016)(Figure 1.3). Another recent study has shown that in 
mice H3.3 has a role in contextual fear memory and motor learning highlighting the growing 
importance of H3.3 in the brain lately (McNally et al., 2016). With the increasing appearance 
of techniques and results the role of H3.3 in brain will eventually grow even more. 
 
Figure 1.3: Roles for H3.3 turnover in brain. Reproduced with permission from (Wenderski and Maze, 2016) 
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1.3. Histone H3 mutations in cancer 
Recently exome sequencing has identified mutations in H3, which are involved with 
paediatric GBM and to a lesser degree with adult GBM (Schwartzentruber et al., 2012; Wu et 
al., 2012). The identified mutations were found in two residues of the H3 tail: lysine 27 was 
mutated to methionine and glycine 34 was mutated to arginine or valine. Both mutations 
affect the PTMs of lysine 27 and lysine 36 (Lewis et al., 2013) that have important roles in 
the regulation of gene expression programs in mammalian cells. Following paediatric glioma, 
H3 mutations have been already identified in other cancers such as chondroblastoma and 
giant cell tumors of the bone (Behjati et al., 2013; Maze et al., 2014)(Table 1.2). These 
findings strongly support a role for H3.3 in cancer progression. 
Table 1.2. Core histones variants in human disease. Reproduced with permission from (Maze et al., 2014) 
H3 mutations found in GBM are predominantly in the two genes encoding H3.3 (H3f3A and 
H3f3B) and with less frequency in H3.1 genes (HIST1H3B and HIST1H3C) and are always 
heterozygous mutations. The specificity and the frequency of these mutations (nearly 80% of 
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paediatric DIPGs carry the K27M mutation) allow them to be defined as driver mutations in 
these tumors (Lewis et al., 2013; Vogelstein et al., 2013).  
The mutations are region-specific, with the K27M mutation occurring predominantly in a 
midline region (brain stem, spinal cord and thalamus) and G34R/V is found in the cerebral 
cortex. There is also an age difference in the appearance of these tumors, being the median 
age of diagnosis for K27M of 10.5 years while G34R/V is diagnosed at a median age of 18 
years (Sturm et al., 2012). These data suggest the implication of an early neuronal precursor 
cell (NPC) acquiring the mutation as a first step in the formation of these gliomas. The 
consequence of the K27M mutation is the dominant inhibition of the enzymatic activity of 
the PRC2 complex both in cis and trans resulting in the decrease of the H3K27me3 repressive 
mark in the whole cell as well as a modest increase in H3K27Ac (Lewis et al., 2013). Genome-
wide studies of the H3K27me3 pattern and the gene expression in K27M patient samples 
showed global reduction of H3K27me2, H3K27me3 and DNA methylation. Surprisingly, 
H3K27me3 and EZH2 were found to be locally increased in hundreds of gene loci (Bender et 
al., 2013; Chan et al., 2013) related with various cancer pathways. These results strongly 
suggest that the K27M mutation reshapes the epigenetic landscape and the gene expression 
of the cell through changes in H3K27me3 and DNA methylation. 
The H3.3K27M protein strongly precipitates with EZH2, suggesting an interaction between 
the EZH2 active site and K27M (Chan et al., 2013). Furthermore, in vitro studies have shown 
that a K27M peptide is enough to block PRC2 activity (Brown et al., 2014; Lewis et al., 2013). 
K27M inhibition of PRC2 activity is equivalent to GSK343 inhibition, a well-known chemical 
EZH2 inhibitor (Bender et al., 2013). The use of a brain stem mouse glioma model based on 
the overexpression of the platelet-derived growth factor (PDGF) in combination with the 
expression of H3K27M was sufficient to significantly decrease H3K27me3 and increase 
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H3K27Ac (Lewis et al., 2013). In addition, the combination of a p53 mutation and H3K27M 
expression in Nestin expresing progenitor cells in the neonatal mouse brain did not induce 
gliomas but was enough to induce proliferating ectopic cell clusters in 72% of the mice while 
H3.3 wildtype expression in combination with a p53 mutation was not sufficient to induce 
proliferating ectopic cell clusters (Lewis et al., 2013). However, K27M expression in 
undifferentiated human ES cells or in primary human astrocytes did not induce proliferation 
(Funato et al., 2014) pointing at a cell type and developmental stage specificity for the K27M 
phenotype. A recent study, involving the use of a mouse model consisting in NSC expressing 
PDGFB and tagged H3.3K27M in addition to primary patient-derived DIPG cell lines showed 
that H3.3K27M potentiates tumorigenesis as well as that the residual PRC2 activity is 
required for the proliferation of H3.3K27M-expressing DIPGs (Mohammad et al., 2017). In 
addition, the data from the study supported the potential of EZH2 as a therapeutic target in 
these tumors.  
Combined efforts in sequencing of paediatric and adult GBM have raised some light into the 
complexity of these tumors. As a consequence different subgroups of gliomas have been 
proposed based on criteria like coexisting mutations, methylation patterns or gene 
expression analysis (Jones and Baker, 2014; Sturm et al., 2012)(Figure 1.4). The K27 
subgroup is characterized by the K27M mutation and includes tumors from almost 
exclusively midline locations as DIPGs and some rare tumors in the basal ganglia and the 
spinal cord. Additionally, the K27 subgroup shows a significantly lower expression of the 
ventral telencephalic marker FOXG1 than other subgroups. Opposite to the G34 subgroup, 
the K27 subgroup also displayed OLIG2 expression, a marker for diffuse gliomas (Ligon et al., 
2004). Furthermore, OLIG2-positive progenitor-like cells of the subventricular zone (SVZ) 
have been suggested as potential glioma-initiating cells (Wang et al., 2009). The specificity of 
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the H3K27M mutation in terms of tumor location and different expression of neuronal 
lineage markers suggests a difference in the cell of origin of these tumors which still remains 
to be proven.  
Figure 1.4. Summary of key molecular and biological characteristics of GBM subgroups. Reproduced with permission from (Sturm et al., 
2012). 
Sequencing results have shown that paediatric GBMs present frequent alterations in the 
canonical cancer pathways also altered in adult GBM, the receptor tyrosine kinase (RTK)-
RAS-PI3K pathway, the TP53 pathway and the RB pathway (Cancer Genome Atlas Research, 
2008; Parsons et al., 2008). However, the specific members of the pathways mutated are 
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different between adult GBMs and paediatric GBMs (Sturm et al., 2014)(Figure 1.5). 
Concerning the (RTK)-RAS-PI3K pathway, paediatric GBMs present mutations in the genes 
PIK3R1 and PIK3CA. These genes encode the regulatory and catalytic subunits p85 and 
p110α of the PI3Kα, respectively. Homozygous mutations of the tumor suppressor gene 
PTEN are rare but present in paediatric GBMs and cause a loss-of-function phenotype. The 
most common member of the pathway mutated in paediatric GBMs is the platelet-derived 
growth factor receptor-α (PDGFRA) being amplified and/or mutated in around 30% of the 
cases (Jones and Baker, 2014). Additionally, the mesenchymal epithelial transition factor 
(MET) and the insulin-like growth factor 1 receptor (IGF1R) are also found mutated in 
paediatric GBMs (Bax et al., 2010; Paugh et al., 2011; Paugh et al., 2010; Puget et al., 2012; 
Qu et al., 2010). Mutations in TP53 are present in approximately 55% of paediatric GBMs 
(Buczkowicz et al., 2014; Schwartzentruber et al., 2012; Wu et al., 2014) with also 9-23% of 
mutations in DIPGs affecting the gene PPM1D which has a role downstream of p53 in the 
DNA damage response (Wu et al., 2014). Finally, the RB pathway is considerably less 
mutated in paediatric GBMs than in adult GBMs. Homozygous deletion of cyclin-dependent 
kinase inhibitor 2A (CDKN2A) are rare in DIPGs but are represented in 25% of non-brain stem 
paediatric gliomas. Additionally, amplification of CDK4, CDK6 or CCND1 (Cyclin D1), CCND2 
or CCND3 (all of them components of the cyclin-CDK complex in charge of the 
phosphorylation of RB at the G1 checkpoint) are found mutated in paediatric brain tumors 
from both the brain stem and the cortex (Bax et al., 2010; Paugh et al., 2011; Qu et al., 
2010).  
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Figure 1.5. Recurrent mutations activate PI3K and MAPK signalling pathways in paediatric high-grade glioma. Reproduced with 
permission from (Jones and Baker, 2014). 
1.4. High grade brain tumor model 
1.4.1. RCAS-TVA system 
The Replication-Competent Avian sarcoma-leukosis Virus (ASLV) with long terminal repeats 
(LTR) and splice acceptor (RCAS) vectors has been used for the introduction and expression 
of genes in both cell culture and animal model systems. The RCAS vectors have the ability to 
infect cells that have the avian receptor tv-a(Bates et al., 1998; Bates et al., 1993) and which 
are actively dividing(Fritsch and Temin, 1977; Humphries et al., 1981; Varmus et al., 1977). 
The RCAS-TVA system has been used to express genes in transgenic mice, which have been 
introduced with the tv-a receptor under the control of a cell lineage-specific promoter to 
generate murine models of specific cancers (Fisher et al., 1999; Holland and Varmus, 1998). 
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Contrary to other oncogenic viruses the RCAS vector contains a full complement of viral 
genes plus the oncogene src.  
Figure 1.6. Production of avian retroviruses and tissue-specific somatic retroviral gene transfer in vivo using the RCAS/TVA system. 
Adapted with permission from (von Werder et al., 2012) 
Taking advantage of this the src gene can be substituted by an endogenous sequence and 
maintain its replication capability (Oh et al., 2002). This method has been used for the 
induction of brain tumors in mice using Nestin-tva transgenic mice and the overexpression of 
a combination of oncogenes through the RCAS vector (Figure 1.6)(Hughes, 2004). Upon 
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intracranial injection of the virus particles into the SVZ of newborn mice, Nestin-expressing 
cells, which are the neural progenitor cells, are infected with the combination of RCAS 
vectors. The brain tumors generated by this method highly mimic the histology of the human 
brain tumors (Huse et al., 2013; Huse and Holland, 2009). The combined expression of 
PDGFB and a constitutively active AKT produced 100% gliomas of which 60% were high-
grade GBMs (Zhu et al., 2014). 
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2. Aim 
DIPG is one of the leading cancer-related causes of death in children and its treatment has 
not seen any improvement over the last decades. However, recent studies have spread 
some hope in changing this situation due to the growing amount of knowledge uncovered. 
Our lab developed a robust HGG model making use of the RCAS/TVA system. The aim of this 
study is to establish a mouse model for DIPG utilizing our current mouse model. This will 
include: 
• introduction of the tagged H3.3/K27M flox into our existing HGG model 
• validation of the model by histology analysis, marker expression (loss of H3K27me3 and 
recovery of H3K27me3 upon tamoxifen treatment) 
• in vivo tumor growth monitoring by BLI 
• optimization of the mouse model by relocation of the induction site to the pons 
Over the last years several studies have linked H3.3 with important roles in the brain like 
contextual fear memory, motor learning, cognition and synapses. Furthermore, histone H3.3 
turnover has been proposed to have a greater role due to the H3.3 pool reaching over 90% 
of the total H3 in the adult brain. In order to contribute, this study aims to develop tools to 
study H3.3 activity in the brain: 
• histone H3.3 tracing in living behaving animals 
• establishment of a mouse line over-expressing an inducible GFP tagged H3f3a 
• establishment of a mouse line over-expressing an inducible RFP tagged H3f3b  
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3. Materials and Methods 
3.1. Buffers and solutions 
A “MilliQ Water Purification System” (Millipore) was used for the preparation of aqueous 
solutions. 
Solution Composition 
4% PFA (pH 7.4) 4 gr paraformaldehyde in 100 ml PBS 
DNA Loading buffer (10 ml) 9.5 ml Formamide, 5 mg bromophenolblue, 5 mg xylencyanol 0.5 mg of 0.5 M EDTA 
Eosin (0.1%) Eosin (0.5%) diluted 1:5 in 70% ethanol plus 5 drops of Glacial Acid 
Injection Buffer 10mM Tris-HCL pH 7.5, 0.1mM EDTA (pH 8.0), 100mM NaCl, H2O Aqua ad iniectabilia Braun 
NID-buffer/500ml 
25ml 1M KCl, 5ml 1M Tris-HCl PH8.3, 
1ml 1M MgCl2, 0.5ml 100mg/ml gelatin, 22.5ml 
10%NP4O, 22.5ml 10%Tween20, 424ml H2O, add 1% 
ProteinaseK (10mg/ml) freshly 
PBST (Triton X-100) PBS containing 0.1% Triton X-100 
PBST (Tween 20) PBS containing 0.1% Tween 20 
Phosphate buffered saline (PBS) 137 mM NaCl, 2.7mM KCL, 9.2 mM Na2HPO4, 1.8Mm KH2PO4 
TE (Tris-EDTA) 10 mM Tris/HCl pH 8.0, 1 mM EDTA 
Table 3.1. List of buffers and solutions. 
3.2. Cell culture reagents 
Reagent (Catalog number) Supplier 
Accutase (A6964-100ML) Sigma Aldrich, USA 
Dulbecco’s Modified Eagle’s Medium (30-2002) 
ATCC, UK 
FBS (30-2020) 
Fugene HD Transfection Reagent (E2311) Promega, Germany 
Penicillin/Streptomycin (15140122) 
Gibco Invitrogen, USA 
Phosphate Buffered Saline (14190250) 
Table 3.2. List of cell culture reagents. 
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3.3. General Reagents 
Reagent (Catalog number) Supplier 
Agarose for PFGE (A2929-25G) Sigma Aldrich, USA 
CHEF DNA Size Standard-Lambda Ladder 
(1703635) BioRad, USA 
Concentrated Antigen Retrieval Citra Solution 
(HK086-9K) Biogenex, USA 
Diaminobenzidine tablets (D4293-50SET) Sigma Aldrich, USA 
dNTP Mix 10MM 1ml (10319879) Thermo Scientific, USA 
Ethidium Bromide (1239-45-8) BioRad, USA 
GelRed in water (10000X) (M3199.5000) Genaxxion, Germany 
Hydrogen peroxide 30% (A1134-1000) Applichem, Germany 
L-Arabinose (A3300) USBiological, USA 
MassRuler Express Reverse DNA Ladder Mix 
(SM1293) Fermentus, USA 
Millipore Membran VMW PO2500 / VM 0.025µm Millipore, USA 
Normal Swine Serum (X0901) Dako, USA 
Pap Pen Immunostaining Pen (MKP-1) Kisker Biotech, Germany 
PFA (0335.3) Roth, Germany 
Sunflower Seed oil (S5007-1L) Sigma Aldrich, USA 
VECTASTAIN ABC HRP Kit (PK-4000) Vector Laboratories, USA 
X-tracta disposable gel extraction tool (N2000-
0100) Starlab, UK 
Table 3.3. List of general reagents. 
3.4. Drugs 
Drug Supplier 
Ampicillin (A1593) 
Sigma Aldrich, USA Chloramphenicol (C0378) 
Tamoxifen free base (T5648-5G) 
Isoflurane (47006XN) IsoFlo, Germany 
Table 3.4. List of drugs. 
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3.5. Instruments 
Instrument Supplier 
Bio-rad CHEF-DR III System 
BioRad, USA 
Bio-rad gene pulser electroporator 
Centrifuge 5424R 
Eppendorf, Germany 
Centrifuge 5804R 
Ecotron Infors-HT, Switzerland 
Heating block QBT Grant Instruments , UK 
IVIS Lumina II In Vivo Imaging System Perkin Elmer, USA 
Leica RM 2255 microtome Leica, Germany 
Multitron pro Infors-HT, Switzerland 
NanoDrop ND-1000 spectrometer NanoDrop, USA 
ProFlex PCR System Thermo Fisher, USA 
Ultraspec III spectrophotometer Pharmacia (Pfizer), USA 
UV Gel Documentation BioRad, USA 
Zeiss Axiophot 
Zeiss, Germany 
Zeiss Axioskop 40 microscope 
Zeiss Cellobserver 
Zeiss LSM 700/780/880 
Table 3.5. List of instruments. 
3.6. Kits 
Kit (Catalog number) Supplier 
Centrifugal Filter Units (MRCF0R030) Millipore, USA 
D-Tube Dialyzer Maxi, MWCO 12-14 kDa (71510-3) 
Kapa2g Fast Readymix with Dye (KAPBKK5101-03) KAPA Biosystems, USA 
QiaQuick gel extraction Kit (28706) 
Qiagen, Germany 
QiaPrep mini prep Kit (27106) 
QIAGEN Large-construct Kit (12462) 
QIAGEN Plasmid maxi Kit (12163) 
Vectashield® Hard+Set Mounting Medium  (H-1400) Linaris, Germany 
Table 3.6. List of kits. 
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3.7. Vectors 
Vector Supplier 
H3f3a BAC (RP24-252A14) BACPAC Resources Center, Children's Hospital Oakland 
Research Institute, California, USA H3f3b BAC (RP24-205P9) 
H3f3a-GFP-ERT2 BAC Modified from H3f3a BAC 
H3f3b-RFP-ERT2 BAC Modified from H3f3b BAC 
pcDNA3.1(+) Thermo Fisher Scientific, Germany 
pIndu-creERT2 Gunther Schütz, DKFZ, Germany 
pIndu-GFP-ERT2 
Modified from pIndu-creERT2 
pIndu-RFP-ERT2 
RCAS-AKT Eric C. Holland, Memorial Sloan-Kettering Cancer Center, New York, USA 
RCAS-GFP Eric C. Holland, Memorial Sloan-Kettering Cancer Center, New York, USA 
RCAS-H3.3-GFP 
Modified from RCAS-AKT 
RCAS-K27M-GFP 
RCAS-PDGFB Eric C. Holland, Memorial Sloan-Kettering Cancer Center, New York, USA 
Table 3.7. List of vectors. 
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3.8. Antibodies 
Antibody (Dilution; Catalog number) Supplier 
Chicken anti-GFP (1:1000 IF/IHC, ab13970) Abcam, UK 
Mouse anti-PCNA (1:400 IF; NA03) Calbiochem, USA 
Rabbit anti-Ki67 (1:500 IF, 1:1000 IHC; ab15580) Abcam, UK 
Rabbit anti-H3K27me3 (1:1000 IF, 1:200 IHC; 
9733s) Cell Signaling, USA 
Rabbit anti-H3K27me3 (1:200 IHC; pAb-069-050) Diagenode, Belgium 
Goat anti-Chicken Biotinylated (1:400; BA9010) Vector Laboratories, 
USA Goat anti-Rabbit Biotinylated (1:400; BA1000) 
Donkey anti-Rabbit Alexa 594 (1:400; A21207) 
Life Technologies, 
USA Goat anti-Chicken Alexa 488 (1:400; A11039) 
Goat anti-mouse Alexa 633 (1:400; A21050) 
Table 3.8. List of antibodies. 
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3.9. Enzymes 
Enzyme Supplier 
Proteinase K (A3830,0025) AppliChem, Germany 
Phusion High-Fidelity DNA Polymerase 
(M0530S) 
New England Biolabs, 
USA 
 
T4 DNA Ligase (M0202S) 
AgeI-HF (R3552S) 
BamHI (R0136T) 
BamHI-HF (R3136T) 
ClaI (R0197S) 
EcoRI (R0101S) 
EcoRV (R0195S) 
EcoRV-HF (R3195S) 
HindIII (R0104S) 
KpnI (R0142S) 
MluI-HF (R3198S) 
NheI (R0131S) 
NheI-HF (R3131S) 
NotI (R0189S) 
NotI-HF (R3189S) 
PmeI (R0560S) 
SnaBI (R0130S) 
SwaI (R0604S) 
XbaI (R0145S) 
XhoI (R0146S) 
Table 3.9. List of enzymes. 
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3.10. Oligonucleotides 
Product 
name  Sequence 
Product 
Size (bp) 
H3f3a left 
homology 
arm 
Forward  
Reverse 
5’-GCCTCAGGTACCTACGTAAGGATGAGGACG-3’ 
5’-CAGTCGTAGCGGCCGCAGCACGTTCTCCGCG-3’ 403  
H3f3a right 
homology 
arm 
Forward  
Reverse 
5’-TCAGGATCTCTAGATAAGAGTCCACTATG-3’ 
5’-TCCTATGCTAGCTACGTATAGTGAATGGAT-3’ 443 
GFP (pIndu) Forward  Reverse 
5’-ATTAATATGCGGCCGCTGCGGTACCGCGGGCC-3’ 
5’-GCAGATGGCTCGAGATCGCCCTTGTACAGCTCGTC-3’ 790 
H3f3b left 
homology 
arm 
Forward  
Reverse 
5’-GCCTCAGGTACCTACGTAGGCAGAGGGCTG-3’ 
5’-CACTCCTAGGATCCAGCTCTCTCCCCCCG-3’ 501 
H3f3b right 
homology 
arm 
Forward  
Reverse 
5’-TGAGGATATCTAGATAAGTTGAAGCGGTT-3’ 
5’-TCCTATGCTAGCTACGTATGGTTAAACACT-3’ 400 
RFP (pIndu) Forward  Reverse 
5’-TTGCTGTTGGATCCGACAACACCGAGGAC-3’ 
5’-CTACATCACTCGAGATCGCCCTGGGAGCCGGAGTG-3’ 706 
H3.3-GFP 
loxp and 
K27M-GFP 
loxp 
Forward  
Reverse 
5’TACGGCCGCGGCCGCATAACTTCGTATAGGATACCTTATA
CGAAGTTATATGGCACGTACCAAGC-3’  
5’ACATCGCATCGATATAACTTCGTATAAGGTATCCTATACGA
AGTTATTTACTTGTACAGCTCGTC-3’ 
1257 
H3f3b wt 
band 
Forward  
Reverse 
5’-CACTCTTCCCATTCATCCTG-3’ 
5’-CATGCCCAAAGACATCCAGT-3’ 199 
H3f3b mt 
band 
Forward  
Reverse 
5’-GGACAGCTTCATGTAGTCGG-3’ 
5’-CATGCCCAAAGACATCCAGT-3’ 310 
H3f3a wt 
band 
Forward  
Reverse 
5’-TTTCCCCTCATAGTGGACTC-3’ 
5’-GTTCCAATACACTTCCTCTG-3’ 415 
H3f3a mt 
band 
Forward  
Reverse 
5’-AGCATGCCTGCTATTGTC-3’ 
5’-CCATGATCAGGTCCACCTTC-3’ 915 
Table 3.10. List of oligonucleotides with their product name and size. 
3.11. Animal housing and Tamoxifen (TAM) treatment 
The animals were housed according to international standard conditions and all animal 
experiments confined to local and international guidelines for the use of experimental 
animals. Nestin-Tva mouse line was kindly provided by Eric Holland. Nestin-CreERT2 mouse 
line was generated as described elsewhere. The line has been successfully used to target 
both SVZ and SGZ NSCs via TAM injection (Liu et al., 2008; Liu et al., 2010). TAM (Sigma) was 
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dissolved in sunflower seed oil (Sigma) with 10% pure Ethanol to prepare a 10mg/ml 
solution. Intraperitoneal injection was performed as 1mg/day for 10 days. The health of the 
animals was monitored every day and was scored according to criteria in Table 3.11. After 
reaching a score of 10 animals were monitored at least twice per day and upon reaching a 
score of 20 animals were sacrificed. 
Category Observation Points 
Body weight 
Unaffected or increased 0 
Weight reduction <5% 1 
Weight reduction 5-10% 5 
Weight reduction 10-20% 10 
Weight reduction >20% 20 
General condition 
Smooth skin; Body openings clean; Eyes 
clear 0 
Fur defects (reduced or exaggerated 
body care) 1 
Fur blunt, disorganized, unkempt body 
openings, eyes cloudy; Increased 
muscle tone, slight hydrocephaly 
5 
Dirty skin, glued or moist body 
openings, abnormal posture, opaque 
eyes; High muscle tone 
10 
Cramps, paralysis (trunk muscles, 
extremities); Breathing; Animal feels 
cold; Severe hydrocephaly 
20 
Spontaneous 
behaviour 
Normal behavior (sleeping, reaction to 
blows and touch, curiosity, social 
contacts) 
0 
Slight deviations from normal behavior 1 
Unusual behavior, restricted motor 
function or hyperkinetics 5 
Self-isolation, lethargy; Pronounced 
hyperkinetics or behavioral 
stereotypes; coordination disorders 
10 
Painfulness when grabbing; Self -
amputation (autoaggression) 20 
Table 3.11. Criteria to euthanize experimental animals. 
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3.12. Polymerase Chain Reaction 
Polymerase Chain Reactions were performed using either a Kapa2g Fast Readymix with Dye 
kit or a mix containing Phusion High-Fidelity DNA Polymerase. The PCR mix reagents and 
their reaction conditions are listed in Table 3.12, 3.13 and 3.14, respectively.  
Kapa2g PCR Volume 
2X Kapa2g Fast Readymix with Dye 7 µl 
Forward primer (10 pmol) 0.5 µl 
Reverse primer (10 pmol) 0.5 µl 
DNA 2 µl 
H2O 4 µl 
Total 14 µl 
Table 3.12. PCR program for Kapa2g reaction. 
Phusion PCR Volume 
Phusion High-Fidelity DNA polymerase 0.2 µl 
5X Phusion High-Fidelity DNA polymerase 
Buffer 3 µl 
dNTPs 2 µl 
Forward primer (10 pmol) 1 µl 
Reverse primer (10 pmol) 1 µl 
DNA 2 µl 
H2O 5.8 µl 
Total 15 µl 
Table 3.13. PCR program for Phusion reaction. 
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Product Name Initial Denaturation 
Denatura
tion 
Anneali
ng Extension 
Cycle 
number 
Final 
Extension 
H3f3a left 
homology arm 
94°C, 5 min 94°C, 30 sec 
64°C, 
30 sec 
72°C, 30 
sec 
35 72°C, 10 min 
H3f3a right 
homology arm 
H3f3b left 
homology arm 
H3f3b right 
homology arm 
GFP (pIndu) 
72°C, 45 
sec 
RFP (pIndu) 
H3.3-GFP loxp 
56°C, 
30 sec 
K27M-GFP loxp 
H3f3a BAC wt 
band 
72°C, 30 
sec 
H3f3a BAC mt 
band 
58°C, 
30 sec 
72°C, 1 
min 
H3f3b BAC wt 
band 
56°C, 
30 sec 72°C, 45 
sec H3f3b BAC mt 
band 
58°C, 
30 sec 
Table 3.14. PCR conditions. 
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3.13. Enzymatic restrictions  
Template (µl) Product Length (bp) 
Enzyme 
1 (µl) 
Enzyme 2 
(µl) 
Buffer 
(µl) 
BSA 
(µl) 
H2O 
(µl) 
pIndu creERT2 
(2.3) (3 µg) 
pIndu 
creERT2 5498 NheI (1) n/a 
NEBuffer 
2 (5) 
n/a 
41.7 
H3f3a right arm 
PCR (2) (1 µg) 
H3f3a right 
arm 425 XbaI 
(0.5) 
NheI 
(0.5) 
NEBuffer 
2 (2) 
15 
H3f3b right arm 
PCR (2.3) (1 µg) 
H3f3b right 
arm 
382 
 14.7 
pcDNA 3.1+ (3.1) 
(3 µg) pcDNA 3.1+ 5428 
NotI-HF 
(1) KpnI (1) 
NEBuffer 
2 (5) 39.9 
H3f3a left arm 
PCR (2.4) (1 µg) 
H3f3a left 
arm 385 
NotI-HF 
(0.5) KpnI (0.5) 
NEBuffer 
2 (2) 
14.6 
 
pcDNA 3.1+ (3.1) 
(3 µg) pcDNA 3.1+ 5428 
BamHI-
HF (1) KpnI (1) 
NEBuffer 
1 (5) 39.9 
H3f3b left arm 
PCR (1.8) (1 µg) 
H3f3b left 
arm 483 
BamHI-
HF (0.5) KpnI (0.5) 
NEBuffer  
1 (2) 15.2 
pcDNA 3.1+ 
H3f3a left arm 
(2.3) (1 µg) 
pcDNA 3.1+ 
H3f3a left 
arm 
5748 NotI 
(0.5) 
XhoI (0.5) NEBuffer 3 (2) 
14.7 
GFP PCR (1.5) (1 
µg) GFP 770 15.5 
pcDNA 3.1+ 
H3f3b left arm 
(2.5) (1 µg) 
pcDNA 3.1+ 
H3f3b left 
arm 
5897 BamHI 
(0.5) 
14.5 
RFP PCR (2.1) (1 
µg) RFP 686 14.9 
pIndu creERT2 
(2.3) (3 µg) ERT2 959 
BamHI 
(1) XhoI (1) 
NEBuffer 
3 (5) 40.7 
pIndu creERT2 
H3f3a right arm 
(2) (2 µg) 
pIndu H3f3a 
right arm 4310 
HindIII 
(1) 
BamHI 
(1) 
NEBuffer 
3 (2) 14 
pcDNA 3.1+ 
H3f3a left arm-
GFP (2.1) (1 µg) 
H3f3a left 
arm-GFP 1155 
HindIII 
(0.5) XhoI (0.5) 
NEBuffer 
2 (2) 14.9 
pIndu creERT2 
H3f3b right arm 
(1.8) (2 µg) 
pIndu H3f3b 
right arm 4363 KpnI (1) 
BamHI-
HF (1) NEBuffer 
1 (2) 
14.2 
pcDNA 3.1+ 
H3f3b left arm-
RFP (2.6) (1 µg) 
H3f3b left 
arm-RFP 1161 
KpnI 
(0.5) XhoI (0.5) 14.4 
H3f3a BAC (3.5) 
(5 µg) Band pattern Several EcoRV (1) ClaI (1) 
CutSmart 
(3) 
21.5 
H3f3b BAC (4) (5 
µg) 21 
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pIndu H3f3a-
GFP-ERT2 (1.1) 
(1.5 µg) 
H3f3a arms-
GFP-ERT2 4019 
SnaBI (1) n/a 
CutSmart 
(2) 
n/a 
15.9 
pIndu H3f3b-
RFP-ERT2 (1.5) 
(1.5 µg) 
H3f3b arms-
GFP-ERT2 3991 15.5 
H3f3a arms-GFP-
ERT2 (30) (0.75 
µg) 
H3f3a arms-
GFP-ERT2 4019 CutSmart 
(4) 
5 
H3f3b arms-GFP-
ERT2 (30) (0.80 
µg) 
H3f3b arms-
GFP-ERT2 3991 5 
H3f3a-GFP-ERT2 
BAC (3) (5 µg) Band pattern Several 
EcoRV-
HF (1) XhoI (1) 
CutSmart 
(5) 40 
H3f3b-RFP-ERT2 
BAC (2.3) (5 µg) Band pattern Several 
BamHI 
(1) 
NEBuffer 
3 (5) 40.7 
H3f3a-GFP-ERT2 
Amp- BAC (3.5) 
(5 µg) 
Band pattern Several AgeI-HF (1) 
n/a 
CutSmart 
(5) 
40.5 
H3f3b-RFP-ERT2 
Amp- BAC (4) (5 
µg) 
Band pattern Several NheI-HF (1) 41 
H3f3a-GFP-ERT2 
Amp- BAC (35) 
(50 µg) 
Linearized 
H3f3a BAC Several PmeI (5) 
CutSmart 
(10) 50 
H3f3b-RFP-ERT2 
Amp- BAC (40) 
(50 µg) 
Linearized 
H3f3b BAC Several 
MluI-HF 
(5) SwaI (5) 
NEBuffer 
3 (10) 40 
pBabe H3.3 (1) 
(1 µg) H3.3 411 
EcoRI 
(0.5) 
BamHI 
(0.5) 
NEBuffer 
3 (2) 2 
14 pBabe 
H3.3K27M(1) (1 
µg) 
K27M 411 
p-eGFP-N1 (1.2) 
(2 µg) p-eGFP-N1 4700 13.8 
H3.3-GFP loxp 
PCR (2.1) (1 µg) H3.3-GFP loxp 1237 ClaI (0.5) NotI (0.5) NEBuffer 
2 (2) 0.5 
14.4 
K27M-GFP loxp 
PCR (2.3) (1 µg) 
K27M-GFP 
loxp 1237 14.2 
RCAS-Akt (1.8) (3 
µg) RCAS 10000 ClaI (1) NotI (1) 13.7 
Table 3.15. Enzymatic restrictions conditions. 
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3.14. DNA Ligation 
DNA ligation reactions were incubated for 4 hours at room temperature. The amount of DNA 
was calculated to maintain a ratio of 1:3 between the vector and the insert; with the vector 
being 50 fmol and the insert 150 fmol. The reaction volumes for each ligation are shown in 
Table 3.16. 
 
Ligation Vector 
DNA (µl) 
Insert DNA (µl) 10X Ligation 
Buffer (µl) 
T4 DNA 
Ligase (µl) 
H2O 
(µl) Vector Inserts 1 2 
pIndu creERT2 
(NheI cut) 
Control 
4 
n/a 
n/a 
 
2 1 
13 
H3f3a right 
arm 5.5 7.5 
H3f3b right 
arm 4.8 8.2 
pcDNA 3.1+ 
(NotI/KpnI cut) 
Control 
3.6 
n/a 13.4 
H3f3a left 
arm 4.5 8.9 
pcDNA 3.1+ 
(BamHI/KpnI 
cut) 
Control 
3.2 
n/a 13.8 
H3f3b left 
arm 4 9.8 
pcDNA 3.1+ 
H3f3a left arm 
(NotI/XhoI cut) 
Control 3 n/a 14 
GFP 6 8 
pcDNA 3.1+ 
H3f3b left arm 
(BamHI/XhoI 
cut) 
Control 
3.4 
n/a 13.6 
RFP 5.2 8.4 
pIndu H3f3a 
right arm 
(HindIII/BamHI 
cut) 
Control 
3 
n/a 14 
H3f3a left 
arm-GFP + 
ERT2 
4.2 5 4.8 
pIndu H3f3b 
right arm 
(KpnI/BamHI 
cut) 
Control 
3.5 
n/a n/a 13.5 
H3f3b left 
arm-RFP + 
ERT2 
3.8 5 4.7 
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p-eGFP-N1 
(EcoRI/BamHI 
cut) 
Control 
4.4 
n/a 
n/a 
12.6 
H3.3 10 2.6 
H3.3K27M 6.2 6.4 
RCAS (ClaI/NotI 
cut) 
Control 
4 
n/a 13 
H3.3-GFP 
loxp 4.3 8.7 
K27M-GFP 
loxp 5 8 
Table 3.16. Reaction volumes for ligations. 
3.15. Agarose Gel Electrophoresis 
1% agarose gels were prepared by adding 1.5 mg of agarose to 150 ml 1x TAE buffer. 15 µl of 
10000X GelRed stock solution was added. After the gel polymerized, the wells were loaded 
with a variable amount of PCR product depending of the application. 5 μl of MassRuler 
Express Reverse DNA Ladder Mix (SM1293) was used as a marker. 
3.16. Agarose Gel Extraction 
Agarose gel extraction was done using the QiaQuick Gel Extraction Kit according to the 
manufacturer’s protocol.  
3.17. BAC purification 
H3f3a and H3f3b BAC clones (Clones RP24-252A14 and RP24-205P9 respectively) were 
received from the BACPAC Resource Center of the Children’s Hospital Oakland Research 
Institute (CHORI) as stab-cultures in LB agar containing 12.5 µg/ml chloramphenicol. The 
stab was gently scratched using a sterile pipette tip and transferred to a sterile 1.5 ml tube 
containing 1ml of LB medium. Serial dilutions of 10-3, 10-5 and 10-7 of the BAC clone-
harboring bacteria were made and the dilutions were inoculated in LB agar plates containing 
25 µg/ml chloramphenicol. Plates were then incubated at 37°C overnight. 
Single colonies were picked and inoculated in 5 ml overnight cultures overnight at 37°C with 
shaking. 1 ml of each culture was kept to establish a glycerol stock in case a clone is selected. 
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The remaining 4 ml of the culture was sequentially centrifuged into a 1.5 ml tube for 5 min 
at 10000g. Supernatants were discarded and LB traces were carefully removed after the last 
centrifugation to add 300 ml of Qiagen buffer P1. Bacteria were resuspended by gentle 
pipetting. 300 ml of Qiagen buffer P2 was added and mixed 6-8 times by inverting the tube 
and later incubated at room temperature for 5 min. Finally, 300 ml of Qiagen buffer P3 was 
added and the tubes were mixed by inverting. Tubes were then incubated on ice for 5 min 
and later spun for 10 min at 10000g at 4°C. 
800 ml of the supernatant was transferred to a new tube. BAC DNA was precipitated by 
adding 540 ml of isopropanol and mixed gently by inverting the tube. DNA samples were 
then spun for 10 min at 10000g at 4°C. Supernatant was discarded and 500 ml of 70% (v/v) 
ethanol was added to wash the pellet prior to another centrifugation for 5 min at 10.000g at 
4°C. Supernatant was removed again and samples were spun shortly at room temperature 
before removing all traces of supernatant. Tubes were left open for 2-3 min to allow the 
pellets to dry. BAC DNA samples were dissolved in 40 ml TE pH 8.0 and, due to the difficulty 
of dissolving a BAC compared to a plasmid, the tubes were incubated at 4°C for 2 hours and 
mixed by tipping occasionally. Later the isolated BAC DNA samples were stored at 4°C. 
3.18. Preparation of competent cells for electroporation 
Serial dilutions of 10-3, 10-5 and 10-7 of the SW105 bacterial cells were prepared and plated 
on LB agar plates without antibiotics. Agar plates were incubated for 20 h at 32°C. Single 
colonies from each plate were inoculated into 5 ml LB culture and incubated overnight at 
32°C.  
During the preparation of electroporation-competent bacteria conditions were kept as close 
to 0°C as possible. Glass pipettes were pre-cooled by pipetting a 0°C cold solution prior to 
pipetting the bacteria and the bacteria were kept on ice. Competent bacteria for 
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electroporation were prepared freshly right before electroporation. Next morning 3 h before 
its use 500 ml sterile 10% (v/v) glycerol in H2O was cooled on ice. 2 ml of the overnight 
cultures were transferred to Erlenmeyer flasks containing 50 ml of LB medium and grow for 
3-5 hours. Absorbance at 600 nm was measured after 3 hours until cultures reached 0.45-
0.5. After cultures reached an absorbance of 0.5, they were transferred to pre-cooled 50-ml 
Falcon tubes and spun down at 4000g for 10 min at 0°C in a pre-cooled rotor. Supernatants 
were discarded and the tubes were inverted on a stack of tissue paper at 4°C to dry the 
remaining supernatant. 
Tubes were put back on ice and 50 ml of ice-cold 10% (v/v) glycerol was added to resuspend 
the cells. Samples were centrifuged at 4000g for 10 min at 0°C and two more steps of 10% 
glycerol were performed. After the last wash, supernatant was removed; save for 0.7 ml, 
which was then aliquoted into pre-cooled 1.5 ml tubes with 50 µl/tube. These aliquots were 
used immediately for electroporation. 
3.19. BAC electroporation into competent cells 
100 µl electroporation cuvettes were placed on ice 5 min prior to use. Tubes containing 
aliquots of competent bacteria as well as purified BAC samples (H3f3a and H3f3b BACs) were 
also placed on ice. The electroporations were prepared by pipetting 50 µl of the competent 
bacteria and 1 µl of the purified BAC into the cuvette. The cuvette was placed in the 
electroporation device (BioRAD Gene Pulser) and a pulse was delivered at 2.3 kV with 25 µF 
and the pulse controller was set to 200 Ω. Following the pulse, 1 ml of LB medium was added 
to the cuvette and then the whole volume was transferred to a 1.5 ml centrifuge tube. Two 
additional electroporations were performed for each BAC using 2 µl and 5 µl of the purified 
BAC.  
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All tubes containing electroporated bacteria in LB were incubated for 1 h at 32°C with 
shaking. Two plates from each electroporation were made, one containing 10% of the 
culture volume and another containing the remaining. LB agar plates containing 25 µg/ml 
chloramphenicol were incubated for 20 h at 32°C. 
3.20. Preparation of competent cells for homologous recombination 
The same procedure for the preparation of competent cells for electroporation was used 
with the following modifications: when the cells reached an absorbance of 0.5 at 600 nm the 
culture was transferred to a shaking water bath at 42°C for 15 min to induce the bacterial 
recombinase activity. After the incubation, the flask with the bacterial culture was moved to 
an ice-slurry and shook gently until cooled down to 0°C. Then the culture was incubated for 
20 min on ice. All further steps were done following the previous protocol.   
3.21. Removal of the antibiotic resistance gene 
To remove the antibiotic resistance gene overnight cultures of each validated and 
recombined BAC clones (H3f3a-GFP-ERT2 and H3f3b-RFP-ERT2 BAC) were made in LB 
containing 25 µg/ml chloramphenicol. Next morning 50 ml of LB (25 µg/ml chloramphenicol) 
was inoculated with 1 ml of the overnight culture. Cells were incubated at 32°C with shaking 
until they reached an absorbance of 0.5 at 600 nm. Then 0.5 ml of 10% (w/v) L-Arabinose 
was added. The bacterial culture was then incubated for an additional hour and diluted by 
taking 5 ml and adding it into a new flask with 50 ml of LB supplemented with 25 µg/ml 
chloramphenicol. Another incubation of the diluted cultures was done at 32°C for one hour 
before preparing serial dilutions (10-3, 10-5 and 10-7) and plating them on LB agar plates 
containing 25 µg/ml chloramphenicol. Plates were incubated for 20 h at 32°C. 
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3.22. Purification of H3f3b-RFP-ERT2 BAC fragment for injection using a 
sepharose column 
H3f3b-RFP-ERT2 BAC was purified using a Sepharose CL-4B column. To prepare the 
sepharose column 20 ml of Sepharose CL-4B was poured into a 250 ml beaker. 150 ml of 
injection buffer was added to the beaker and mixed gently by swirling. Afterwards the gel 
was allowed to settle completely. The solution was decanted and another 150 ml of injection 
buffer was added. This step was repeated three more times for a total of 4 washes with the 
injection buffer. After the washes, sepharose was resuspended in 100 ml of injection buffer 
and transferred to a vessel that allowed for degassing of the gel. To degas the gel, the vessel 
was connected to a pump for 15 min, swirling occasionally. Then, the degassed gel was 
transferred to a beaker. 
To prepare the column, a 5 ml Falcon serological pipette was used. Most of the cotton bud 
was removed and the remaining was pushed to the tip of the pipette to prevent the gel from 
flowing out. The column was firmly attached to a holder in a vertical position. The bottom 
part of the column was closed using a pipette tip with parafilm wrapped around it. The 
column was filled with injection buffer up to two-thirds of its height. The beaker with the gel 
was swirled gently to resuspend the sepharose and then the gel was applied with a Pasteur 
pipette to the column filling it up to the top. Once 1 cm of the gel matrix was settled down 
the outflow was open and the eluate was collected in a beaker. Gel was continuously applied 
down the column until the gel reached 2-3 cm from the top of the column. After the packing 
was finished a 50 ml syringe without the piston was connected to the top of the column 
using parafilm and filled with injection buffer. The column was washed with 30 ml of 
injection buffer and then the 50 ml syringe was removed. When there was almost no buffer 
left on top of the gel, the BAC sample (100 µl) was applied. The solution was allowed to 
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enter the gel and then an additional 100 µl of injection buffer was applied. After the buffer 
entered the column another 100 µl of injection buffer was applied to the top of the column 
and allowed to enter. After this second round of 100 µl the column was filled with injection 
buffer, the 50 ml syringe was reattached and filled with injection buffer. 300 µl fractions 
were collected until 40-50 fractions left the column and then the column was stopped. The 
absorbance at 260 nm was measured for every fraction to identify the fractions containing 
the BAC fragments.  
3.23. Purification of H3f3a-GFP-ERT2 BAC fragment for injection by nucleic 
acid extraction, concentration and dialysis 
To purify the H3f3a-GFP-ERT2 BAC fragment the corresponding 110 kb band was excised 
from the agarose gel after running a PFGE. The agarose block was then put inside a Maxi D-
tube dialyzer and placed into an electrophoresis chamber filled with 0.5X TAE buffer. 
Following the manufacturer protocol, an elution time of 90 min at 100 V was used. After 
eluting the DNA fragment into the TAE buffer, the sample was concentrated using Microcon 
Centrifugal Filter columns to a final volume of 100 µl, following the standard protocol 
provided by the manufacturer. The final 100 µl was then pipetted on top of a Millipore 
Membrane floating in a petri dish with 100 ml injection buffer and dialyzed for 3 hours at 
4°C. 
3.24. Pulse Field Gel Electrophoresis 
1% agarose gels were prepared by adding agarose (for PFGE) to 0.5X TAE buffer. After the 
gel polymerized, a piece of a block of the precast ladder (CHEF DNA Size Standard Lambda 
Ladder) was cut and embedded into the first well using some of the agarose previously 
melted. After the marker was casted into the gel, the PFGE was run using a CHEF-DR III 
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System from BioRad according to the manufacturer’s protocol with the following settings: 6 
V/cm, pulse angle 120, initial switching time 0.5 sec, final switching time 20 sec, run time 14 
h and cooling set to 14°C. Later, the PFGE gels were post-stained with Ethidium Bromide 
(1mg/ml solution) when necessary. 
3.25. Bacterial transformation 
Bacterial transformation was done using DH5α E.coli strain. For each reaction, 50 µl of DH5α 
cells was thawed on ice. After thawing, 10 µl of the ligation reaction was added to the 50 µl 
of cells, and the solution was mixed and incubated on ice for 30 minutes. The mixture of cells 
and ligation reaction was then heat-shocked for 90 seconds at 42°C to permeabilize the cells. 
After the heat shock, cells were incubated for 2 minutes on ice. 1 ml of LB medium was 
added to each of the samples and they were left shaking for 1 hour at 37°C before being 
centrifuged at 6000 r.p.m. and the resuspension of the pellet in 200 µl LB medium. The 
resuspended bacteria were then spread into ampicillin agar plates and incubated overnight 
at 37°C. 
3.26. Colony Miniprep 
5 colonies from each transformation group were picked and inoculated into 5 ml LB medium 
with ampicillin. These cultures were incubated overnight shaking at 37°C and miniprep was 
performed according to manufacturer’s protocol using QiaPrep mini prep Kit (27106). 
3.27. Genotyping  
Genomic DNA was isolated from tail tip biopsies using NID buffer plus 1% Protein-kinase K 
and incubating at 56 degrees for three hours. Genotyping of the BAC mouse lines was done 
from tail and/or ear biopsies. Genotyping was performed by PCR following the protocol 
described in Section 3.12 (Table 3.12). 
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3.28. DF-1 cell culture and transfection 
DF-1 chicken cells were used for the production of the different RCAS viruses. They were 
grown in DMEM (ATCC, 30-2002) supplemented with 10% FBS (ATCC, 30-2020) and 1% 
Penicillin/Streptomycin (Life technologies, 15140122) and incubated at 39°C in a humidified 
incubator with 5% CO2. For the transfection of the RCAS constructs a vial of early passage 
DF-1 cells was thawed, expanded and split into cell culture flasks (Greiner bio-one, 690175) 
such that the cells will reach a confluence of 60% on the day of the transfection. To perform 
the transfection, 4 µg of plasmid and 10 µl of FugeneHD (Promega, E231A) were diluted in 
200 µl of Opti-MEM and incubated at room temperature for 15 min. After the incubation, 
the mixture was directly added to the flask containing DF-1 cells. Medium was changed 12 h 
after the transfection and every transfection was checked after 3-5 days under the 
microscope using RCAS-GFP plasmid as a positive control. Transfected cells were used for 
injection into pups 7-14 days post-transfection.  
3.29. Primary brain tumor induction 
To induce primary brain tumors in our mouse model, DF-1 cells were transfected with the 
following constructs: RCAS-AKT, RCAS-PDGFB, RCAS-luciferase, RCAS-GFP, RCAS-H3.3-GFP 
and RCAS-H3.3K27M-GFP. On the day of injection, single cell suspensions of each of the 
cultures were prepared and the concentration was measured. DF-1 cells expressing each of 
the constructs were combined as shown in Table ? and the final concentration of each cell 
type was adjusted to 4x104 cells/µl. 
Group Combination 
GFP RCAS-GFP + RCAS-AKT + RCAS-PDGFB + RCAS-luciferase 
H3.3 RCAS-H3.3-GFP + RCAS-AKT + RCAS-PDGFB + RCAS-luciferase 
K27M RCAS-H3.3K27M-GFP + RCAS-AKT + RCAS-PDGFB + RCAS-luciferase 
Table 3.17. Combination of RCAS constructs injection. 
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1 µl of the cell mixture was injected into one of two different locations in the brains of 
neonatal Nestin-TVA or Nestin-TVA/Nestin creERT2 animals by an intracranial injection using 
a 10 µl Hamilton syringe. First location was the SubVentricular Zone (SVZ) of the 
hippocampus of the right brain hemisphere (red arrow, Figure 3.1) and the second one was 
the pons (blue arrow, Figure 3.2). The coordinates for the intracranial injection in the first 
case were 1/3 of the distance between Bregma and Lambda and 1.5 mm depth. For the pons 
injection, coordinates were 1 mm posterior to Lambda and 3 mm depth. 
  
 
Figure 3.1. Schematic representation of a sagittal cut of the mouse brain showing the location of the intracranial injections. 
3.30. Bioluminescence Imaging 
Detection and monitoring of tumor growth was done by Bioluminescence Imaging (BLI), 
using IVIS Lumina II In Vivo Imaging System (Perkin Elmer). Owing to the fact that our tumor 
model includes the injection of RCAS-luciferase into the mouse brain, tumor cells express the 
luciferase enzyme. This enzyme, in the presence of O2, converts the substrate D-luciferin into 
oxyluciferin and produces light. Animals were given an injection of D-luciferin (Biocat, 7903-
1g-BV) intraperitoneally. D-luciferin was dissolved in PBS and the final concentration 
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administered was 150 mg/Kg of body weight. Following the injection, animals were 
anesthetized using the XGI-8 system provided with the IVIS and imaged by taking 1 picture 
every minute for at least 20 min. The parameters were: exposure time: 1 min (in the case of 
the signal being too high, the exposure time was reduced to 30 sec, 15 sec or 5 sec to avoid 
overexposure), high binning and aperture lens position: F1. Light was then detected by the 
IVIS system and displayed as a pixel image, overlapping with a photograph of the animals 
being imaged. A Region of Interest (ROI) was then drawn over the head of the mouse using 
the Living Image 4.3.1 software provided with the IVIS system and the total signal was 
calculated in photon/sec (p/s). A curve with the measurements of each mouse over the 20 
min (or more when necessary) of imaging was plotted and the peak value was then selected 
as the BLI value for that day as shown in Figure 3.2.  
 
 
 
 
 
 
 
 
 
Figure 3.2. BLI measurement. (A) BLI pictures taken every minute after D-luciferin injection. (B) Bioluminescence (photons per second) 
signal over time, red arrow point at the peak of the signal. 
 
 
 
B A 
                                                                                                                                            Materials and Methods 
 
57 
 
3.31. Tumor tissue sampling 
Following the criteria mentioned in Table 3.11, animals were sacrificed upon reaching a 
threshold of 20 points. Animals were euthanized using a CO2 chamber. To extract the brain 
the head area was soaked with 70% Ethanol and the animal was then beheaded using strong 
scissors. The surface of the skull was revealed by cutting off the skin of the head using 
smaller scissors. The skull was cut into pieces using strategically placed incisions between the 
eyes and parallel to the ears until the upper part of the skull could be separated from the 
brain. Finally, carefully using a small spoon, the brain was removed from the rest of the skull 
and placed in a 15 ml Falcon tube containing 4% PFA for fixation. The brain sample was then 
put through the process described in Table 3.18 for fixation and embedding of the tissue. 
 
Solution Time Temperature Comments 
Fix in 4% PFA overnight 4°C pH 7,2 
PBS 2 X 15 min Room temperature  
70% Ethanol 2 X 30 min Room temperature  
85% Ethanol 60 min Room temperature  
95% Ethanol 60 min Room temperature  
100% Ethanol 60 min Room temperature Change solution once 
Xylol 2 X 60 min Room temperature  
Paraffin 3 X 60 min 60°C  
Paraffin block Indefinite Room temperature  
Table 3.18. Fixation and paraffin embedding protocol. 
3.32. Paraffin sectioning 
Paraffin embedded tissues were sectioned using a microtome (Leica RM 2255). Paraffin 
blocks were placed into the cutting platform and excess of paraffin was removed using a 
blade. The paraffin block was trimmed by 50 µM sections until the tissue sample was 
reached. Once at the desired location, 6 µM sections were cut. After cutting 4-5 sections, 
these sections were transferred to a water bath at 39°C filled with distilled water and 
                                                                                                                                            Materials and Methods 
 
58 
 
allowed to spread. When the tissue expanded and there were no more wrinkles, the sections 
were taken in a slide and placed in a heat block at 39°C for further drying. When the slides 
were dry they were placed into slide boxes and incubated at 37°C overnight. 
3.33. Haematoxylin & Eosin staining 
Haematoxylin & Eosin staining of the paraffin sections was done following the protocol 
shown in Table 3.19. Haematoxylin and Eosin solutions were filtered prior to each use. 
Solution Time 
Xylene 2 X 5 min 
100% Ethanol 2 X 5 min 
70% Ethanol 5 min 
Distilled water 5 min 
Haematoxylin 8 min 
Distilled water Clean shortly 
Running tap water (warm) 5 min 
Eosin (0.1%) 90 sec 
Distilled water Dip in 
70% Ethanol 3 min 
85% Ethanol 3 min 
100% Ethanol 2 X 5 min 
Xylene 2 X 5 min 
Table 3.19. Haematoxylin & Eosin staining protocol. 
3.34. Immunohistochemistry staining 
Immunohistochemistry staining of the paraffin sections was done using the protocol in Table 
3.20. Citrabuffer was prepared by diluting Concentrated Antigen Retrieval Citra Solution 
(Biogenex, HK086-9K) 1:10 in distilled water. H2O2 3% was prepared by diluting Hydrogen 
peroxide 30% (A1134-1000, Applichem) 1:10 in PBS/Methanol (1:1). Normal Swine Serum 
(NSS) was diluted in PBS. The primary antibody was diluted in 5% NSS and the secondary 
antibody was diluted 1:400 in 5% NSS. AB-Complex (PK-4000, Vector Laboratories) was 
prepared 30 min in advance and diluted 1:100 in PBS. Diaminobenzidine was prepared by 
dissolving 1 silver tablet and 1 gold tablet (D4293-50SET, Sigma) in 5ml of distilled water. 
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Day 1 
Solution Time 
Xylene 2 X 5 min 
100% Ethanol 2 X 5 min 
95% Ethanol 2 X 5 min 
70% Ethanol 5 min 
Distilled water 5 min 
PBS 5 min 
Citrabuffer 
Microwave 2 min at maximum watt 
Microwave 8 min at 360 watt 
30 min cool down to room temperature 
PBS 5 min 
3% H2O2 8 min 
PBS 5 min 
Circle sections with PAP-Pen and put them in moist chamber 
5% NSS 30 min 
Primary antibody Overnight, 4°C  
Day 2 
PBS 3 X 5 min 
Secondary antibody 30 min 
PBS 3 X 5 min 
AB-Complex 30 min 
PBS 2 X 5 min 
DAB Variable, stop reaction with water 
70% Ethanol 5 min 
95% Ethanol 2 X 5 min 
100% Ethanol 2 X 5 min 
Xylene 2 X 5 min 
Mount sections using Eukitt 
Table 3.20. IHC staining protocol. 
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3.35. Immunofluorescence staining 
Immunofluorescence staining of the paraffin sections was done following the protocol in 
Table 3.21. Citrabuffer, NSS and primary antibody were prepared as described in Section 
3.34. Secondary antibody was diluted 1:400 in PBST. 
Day 1 
Solution Time 
Xylene 2 X 5 min 
100% Ethanol 2 X 5 min 
95% Ethanol 2 X 5 min 
70% Ethanol 2 X 5 min 
Tap water 5 min 
PBS 5 min 
Citrabuffer 
Microwave 2 min at maximum 
watt 
Microwave 8 min at 360 watt 
30 min cool down to room 
temperature 
PBS 5 min 
Circle sections with PAP-Pen and put them in moist chamber 
5% NSS 30 min 
Primary antibody Overnight, 4°C  
Day 2 (Kept in the dark) 
PBST 3 X 5 min 
Secondary antibody 1 h 
PBST 2 X 5 min 
Mount sections using Vectashield mounting medium 
Table 3.21. Immunofluorescence staining protocol. 
3.36. Laser scanning microscopy imaging and image analysis 
Brightfield and fluorescence pictures of the DF-1 cells in culture were taken using a Zeiss Cell 
Observer Microscope. Brightfield pictures of the DAB stainings were taken using a Zeiss 
Axiophot or a Zeiss AxioScan.Z1 microscope. Fluorescence pictures of the paraffin sections 
after immunofluorescence staining were taken using a Zeiss LSM 700/780/800 microscope. 
All processing and counting of the images were done using either Fiji or Zen (Blue edition) 
software. 
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3.37. Statistical analysis 
Statistical analysis was performed using Sigma Plot version 12.5. Quantitative experiments 
were repeated at least three times independently and the results were presented as mean ± 
s.d. One-Way Analysis of Variance (ANOVA) was used to determine statistical significance 
among three or more groups with a post-hoc Bonferroni t-test for pairwise multiple 
comparison. Survival analysis was presented using a Kaplan-Meier survival curve, and the 
survival curves comparison was done by log-rank test. 
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4. Results 
4.1. Establishment of a DIPG mouse model 
4.1.1. Cloning of RCAS-H3.3-GFP and RCAS-H3.3K27M-GFP 
In order to trace and be able to delete the histone H3.3 using our mouse tumor model we 
tagged H3.3 and H3.3K27M with GFP and flanked the DNA sequence with loxp sites. 
H3.3/H3.3K27M DNA were excised from the pBabe vector as shown in Figure 3.1A and 
cloned into the p-eGFP1-N1 which fused the C-terminus of H3.3/H3.3K27M to the GFP 
protein. Upstream and downstream loxp sites were added by PCR amplification of H3.3-
GFP/H3.3K27M-GFP (Figure 3.1C) and cloned into the RCAS vector substituting the AKT 
insert (Figure 3.1B). Positive colonies were identified (Figure 3.1D) and sequenced to 
confirm the correct sequence for the vectors. 
 
Figure 3.1. Cloning of H3.3 constructs into the RCAS vector. (A) Agarose gel electrophoresis of the pBabe-H3.3 vector after enzymatic 
digestion with BamHI and EcoRI. H3.3 insert can be observed as an approximately 400 bp band. (B) Agarose gel electrophoresis of the 
RCAS-AKT vector after enzymatic restriction with NotI and ClaI. (C) Agarose gel electrophoresis of inserts H3.3-GFP loxp and K27M-GFP loxp 
after PCR amplification. The phusion protein H3.3-GFP loxp can be seen as a 1.2 kb band. (D) Agarose gel electrophoresis of enzymatic 
restriction analysis from bacteria colonies potentially carrying RCAS-H3.3-GFP loxp or RCAS-K27M-GFP loxp. DNA was cut using ClaI and 
NotI, RCAS-AKT is included as a control. (E) Map of the insert region of the vector RCAS-H3.3-GFP loxp. 
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4.1.2. RCAS-H3.3-GFP and RCAS-H3.3K27M-GFP expression in DF-1 cells 
In order to confirm the functionality of the RCAS-H3.3-GFP/RCAS-H3.3K27M-GFP vectors, DF-
1 cells were transfected with both vectors as well as RCAS-GFP as a positive control and 
RCAS-AKT as a negative control. GFP expression was observed to be nuclear in RCAS-H3.3-
GFP/RCAS-H3.3K27M-GFP compared with RCAS-GFP as expected (Figure 3.2B, D and F) and 
3-5 days after transfection the totality of the cells expressed the vector (>95% of the cells).  
 
Figure 3.2. RCAS-H3.3-GFP and RCAS-K27M-GFP expression in DF-1 cells. (A, C, E and G) Brightfield images of DF-1 cells in culture 
expressing RCAS-GFP, RCAS-H3.3-GFP, RCAS-K27M-GFP or RCAS-AKT. (B, D, F and H) Representative fluorescence pictures of DF-1 cells in 
culture expressing RCAS-GFP, RCAS-H3.3-GFP, RCAS-K27M-GFP or RCAS-AKT. 
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4.1.3. In vivo tumor growth can be monitored by Bioluminescence Imaging 
In order to monitor tumor growth in our tumor model, RCAS-luciferase was delivered into 
the SVZ of the mouse brain in combination with the other oncogenes. As shown in Figure 
3.3, light emission (photons per second) from the tumor cells carrying the luciferase enzyme 
was detected with the help of IVIS Lumina II device. Biweekly imaging of the experimental 
animals showed the expansion of the tumor over time (Figure 3.3A and B) 
 
 
 
 
 
 
 
Figure 3.3. Representative BLI of a tumor. (A) BLI pictures showing tumor growth over time. (B) Bioluminescence measurements 
represented as total flux against tumor days (photons/second). 
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4.1.4. A High Grade Glioma model overexpressing H3.3 
Histology analysis of the tumors concluded that tumors resembled HGG and displayed key 
features present in HGG like pseudopalisading necrosis (blue arrows in Figure 3.4A, Figure 
3.4C) and active angiogenesis (red arrows in Figure 3.4A, Figure 3.4B). In addition, tumor 
region showed positive GFP staining indicating the expression of either H3.3-GFP or 
H3.3K27M-GFP. 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4. Histological features of High Grade Glioma model and marker expression. (A) Representative H&E staining of mouse tumor. 
Blue arrows indicate pseudopalisading necrosis and red arrows indicate angiogenesis. (B) High magnification picture showing the 
vascularization present in the tumor. (C) High magnification picture of pseudopalisading cells surrounding a necrotic region. (D, E and F) 
Representative pictures of the same tumor region. D shows H&E staining while E and F show GFP and ki67 IHC staining respectively. 
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A small subset of the tumors showed different tumor compartments with and without GFP 
expression (Figure 3.5A and B). In addition, the majority of the tumors showed regions with 
a mixture of GFP and non-GFP cells (Figures 3.8L, 3.9A and B, C and D, E and F, I and J). 
 
 
 
 
 
Figure 3.5. Tumor shows different compartments according to GFP expression. (A) H&E staining of a tumor induced by the over-
expression of RCAS-AKT, RCAS-PDGFB and RCAS-GFP. (B) GFP IHC staining of the same tumor region showed in A. Green arrows indicate 
the tumor compartments which show GFP expression while the red arrows indicate the region of the tumor without GFP expression. 
 
Since DIPGs are mainly found in the pons, we tested whether we can utilize our mouse 
model to induce tumors in the pons instead of the SVZ by changing the location of the 
injection. As shown in Figure 3.6A and B, specific targeting of the pons by intracranial 
injection was achieved. However, these injections did not result in HGGs. The majority of the 
experimental animals showed different degrees of hydrocephaly (blue arrow, Figure 3.6C), 
large blood clots in the region between the pons and the cerebellum (red arrow in Figure 
3.6C, Figure 3.6D) and small tumor regions that made difficult a histological analysis of the 
tumors (Figure 3.6E). These findings suggest that the tumors provoke an early blockage of 
the cerebrospinal fluid (CSF) resulting in the death of the animals before tumors could be 
fully developed. 
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Figure 3.6. Histological features of tumors arising from the pons. (A) Sagittal cut of the mouse brain after intracranial injection in the pons 
with blue ink. (B) Sagittal schematic view of the mouse brain, red arrow indicates the location of the intracranial injection in the pons. (C) 
H&E staining of a sagittal paraffin section. Blue arrow indicates hydrocephaly and red arrow indicates a blood clot.  (D) Representative H&E 
picture showing a blood clot at the same region as red arrow in C. (E) Higher magnification picture showing the tumor region abode the 
pons.   
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4.1.5. H3.3K27M over-expression reduces H3K27me3 levels 
Immunohistochemistry (IHC) analysis of the H3K27me3 expression in our model showed that 
tumors over-expressing H3.3K27M-GFP had lower levels of H3K27me3 (Figure 3.7). A 
comparison of the H3K27me3 pattern can be seen in Figure 3.7, showing similar staining 
levels for all the groups in the cortex region, which is used as a control (Figure 3.7D, E and F). 
In contrast, K27M expressing tumors (K27M group) showed depleted H3K27me3 levels in 
the tumor region when compared with both control groups, GFP and H3.3 (Figure 3.7A, B 
and C). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.7. K27M-expressing tumors show reduced H3K27me3 compared to control tumors. (A-C) H3K27me3 IHC staining of the tumor 
region of tumors from GFP, H3.3 and K27M group. (D-F) H3K27me3 IHC staining of the cortex of the same brains as in A-C.  
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Figure 3.8. Only cells expressing K27M-GFP lose the H3K27me3. (A, E and I) GFP 
IF staining of tumors from the GFP, H3.3 and K27M group. (B, F and J) H3K27me3 
IF staining of tumors from the GFP, H3.3 and K27M group. (C, G and K) ki67 IF 
staining of tumors from the GFP, H3.3 and K27M group. (D, H and L) Merge IF 
picture of tumors from the GFP, H3.3 and K27M group.  Yellow arrows in L indicate 
examples of K27M-GFP expressing cells that do not show H3K27me3 expression. 
(M) H3K27me3+/GFP+ comparison between groups. One-Way Analysis of Variance 
(ANOVA) was used to determine statistical significance. GFP vs K27M, p<0.002; H3.3 vs K27M, p<0.001. 
 
M 
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Immunofluorescence staining for GFP and H3K27me3 were done to analyze the co-labeling 
of these two markers. For the GFP and H3.3 group, most of the GFP+ cells were double 
positive for GFP and H3K27me3 (Figure 3.8D, H and M) while the K27M group showed 
significantly (GFP vs K27M, p<0.002; H3.3 vs K27M, p<0.001) less amount with almost no 
double positive cells in its GFP+ population (<5%, Figure 3.8L and M). 
4.1.6. H3.3K27M deletion rescues normal H3K27me3 levels 
To analyze the effect of the H3.3K27M deletion in developed tumors, NestinTVA/Nestin 
creERT2 animals were injected with tamoxifen 28 days after tumor induction to induce the 
loxp sites recombination. Upon tamoxifen injection, H3.3-GFP/H3.3K27M-GFP were deleted 
in the recombinase cre + animals which was confirmed by the loss of GFP expression (Figure 
3.9G and K). GFP expression was unaffected in the cre - animals for H3.3 and K27M groups 
as well as for all animals in the GFP group (Figure 3.9A, C, E and I). Tamoxifen injection did 
not affect the significant (GFP cre- vs K27M cre-, p<0.001; H3.3 cre- vs K27M cre-, p<0.001) 
difference in H3K27me3 levels existing between K27M and the control groups in the cre- 
animals (Figure 3.9A and B, E and F, I and J and M). Comparison of co-labeling of GFP+ and 
H3K27me3+ cells between cre+ and cre- animals was not possible because cre+ animals from 
the H3.3-GFP/H3.3K27M-GFP groups did not have GFP expression. Ratio of H3K27me3+ cells 
from total cells was used instead to compare all the groups showing a significant difference 
for K27M cre- group with every other group (K27M cre- vs every group, p<0.001; Figure 
3.9N). K27M cre+ group showed significantly higher H3K27me3 levels than K27M cre- group 
and no difference when compared with the control groups indicating that K27M deletion 
rescued H3K27me3 phenotype. 
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Figure 3.9. Deletion of K27M-GFP rescues H3K27me3 levels. (A, E and I) GFP IF staining of cre- animals from the GFP, H3.3 and K27M 
group. (C, G and K) GFP IF staining of cre+ animals from the GFP, H3.3 and K27M group. (B, F and J) H3K27me3 IF staining of cre- animals 
from the GFP, H3.3 and K27M group. (D, H and L) H3K27me3 IF staining of cre+ animals from the GFP, H3.3 and K27M group. (M) 
H3K27me3+/GFP+ comparison between groups. One-Way ANOVA was used to determine statistical significance. GFP vs K27M, p<0.001; 
H3.3 vs K27M, p<0.001. (N) H3K27me3+/total cells comparison between groups. One-Way ANOVA was used to determine statistical 
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significance. GFP cre- vs K27M cre-, p<0.001; GFP cre+ vs K27M cre-, p<0.001; H3.3 cre- vs K27M cre-, p<0.001; H3.3 cre+ vs K27M cre-, 
p<0.001; K27M cre+ vs K27M cre-, p<0.001. 
4.1.7. K27M over-expression and deletion do not significantly affect survival  
In order to analyze the survival, animals that did not complete the 10 days tamoxifen 
treatment were excluded. Additionally, only the tumors that reached a threshold of 5x105 
p/s 28 days after tumor induction were included in the analysis. There was no significant 
difference in survival within the groups when comparing cre- with cre+ animals, as shown in 
Figure 3.10A, B and C. Kaplan-Meier curves for GFP, H3.3 and K27M cre- groups did not 
shown survival differences (Figure 3.10D). 
 
 
 
 
 
 
 
 
 
 
Figure 3.10. There is not significant difference in survival between K27M over-expressing and control tumors. (A) Kaplan-Meier survival 
analysis between GFP cre+ and cre- groups after TAM treatment. (B) Kaplan-Meier survival analysis between H3.3 cre+ and cre- groups 
after TAM treatment. (C) Kaplan-Meier survival analysis between K27M cre+ and cre- groups after TAM treatment. (D) Kaplan-Meier 
survival analysis between GFP, H3.3 and K27M cre- groups after TAM treatment. 
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4.2. Histone tracing in living behaving animals 
4.2.1. pIndu H3f3a-GFP-ERT2 and H3f3b-RFP-ERT2 cloning 
In order to modified the H3f3a and H3f3b BACs, the pIndu vector was modified to be used 
for the modification of the BACs by homologous recombination. One pIndu vector was 
designed to contain the fusion GFP-ERT2 with two homology arms for H3f3a while the other 
contained RFP-ERT2 with two homology arms for H3f3b (Figure 3.11A). Homology arms were 
designed in a way that the insertion site for GFP-ERT2/RFP-ERT2 were in the last exon of the 
gene sequence right before the stop codon. After recombination GFP-ERT2/RFP-ERT2 will 
replace the stop codon resulting in two BACs containing the sequence for the fusion proteins 
H3f3a-GFP-ERT2 and H3f3b-RFP-ERT2 but also containing the introns and regulatory regions 
upstream and downstream the gene sequences (Figure 3.11B).  
 
 
 
 
 
 
 
 
 
Figure 3.11 pIndu vectors and Bacterial Artificial Chromosomes (BAC) for H3f3a and H3f3b. (A) Maps of the pIndu vectors used to 
modified the BACs by recombination. (B) Maps of each H3f3 BAC showing the backbone region, all genes contained in the BAC and the 
restriction sites used for the final linearization step. 
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H3f3a and H3f3b homology arms were amplified by PCR using their respective BACs as 
templates (Figure 3.12A), ERT2 was cut from the pIndu creERT2 vector and GFP and RFP 
were PCR amplified from RCAS-GFP and RCAS-RFP, respectively (Figure 3.12B). Both 
homology arms plus GFP/RFP and ERT2 were cloned into the pIndu vector using pcDNA 3.1+ 
as an intermediate vector. 
 
 
 
 
 
 
Figure 3.12 PCR amplification of the H3f3 homology arms, GFP and RFP for pIndu cloning. (A) Agarose gel electrophoresis of H3f3 
homology arms after PCR amplification. (B) Agarose gel electrophoresis of the GFP and RFP inserts after PCR amplification. 
4.2.2. H3f3 BACs modification by recombination 
Upon reception of the H3f3a and H3f3b BACs, restriction pattern analysis of the BAC DNA 
was done to confirm the BAC clone identity (Figure 3.13A and B). H3f3a and H3f3b BACs 
were modified by homologous recombination using pIndu H3f3a-GFP-ERT2 and pIndu-RFP-
ERT2 as described before. After the recombination step, antibiotic resistance was removed 
from the BAC by activation of the frt sites flanking the ampicillin resistance gene and 
restriction band pattern analysis confirmed the deletion. Insert region of the BACs (GFP-
ERT2/RFP-ERT2) were sequenced confirming the correct recombination and antibiotic 
resistance removal. 
 
A B 
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Figure 3.13 BAC restriction fragment pattern analysis on agarose gel.  (A) Restriction fragment pattern of H3f3a BAC cleaved with 
ClaI/EcoRV. (B) Restriction fragment pattern of H3f3b BAC cleaved with ClaI/EcoRV. (C) Restriction fragment pattern of H3f3a-GFP-ERT2 
BAC cleaved with AgeI after the antibiotic resistance removal. Restriction fragment pattern of H3f3b-RFP-ERT2 BAC cleaved with NheI after 
the antibiotic resistance removal. 
BAC DNA was linearized and purified prior to microinjection into the zygotes. H3f3a-GFP-
ERT2 BAC was linearized using PmeI restriction enzyme, which removed the BAC backbone 
and the sequence for Sde2 gene also presents while keeping as much upstream and 
downstream sequence as possible (Figure 3.11B). For H3f3b-RFP-ERT2 BAC, the removal of 
four genes (Recql5, Sap30bp, ltgb4 and Galk1) was necessary to avoid collateral effects from 
the over-expression of these genes. Owing to that, H3f3b-RFP-ERT2 was linearized using 
SwaI and MluI sequential digestion which removed the BAC backbone, three of the genes 
completely and deleted all of the exon sequence from Galk1 gene (Figure 3.11B). H3f3b-RFP-
ERT2 was purified using a Sepharose column as described before, and fractions containing 
BAC DNA were identified measuring Absorbance at 260 nm. H3f3b-RFP-ERT2 BAC 
linearization resulted in the BAC excision into three fragments: one of 25 kb containing our 
insert of interest that eluted together with a second one of 42 kb, and a third one of 88 kb 
that eluted later as a second peak in Absorbance. An aliquot of the fractions contained in the 
first peak of Absorbance were run in a PFGE that confirmed the isolation of the 25 kb 
fragment in the first fraction (Figure 3.14A). H3f3a-GFP-ERT2 BAC linearization resulted in 
A B C 
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two fragments: one of 110 kb containing our insert of interest and another one of 70 kb. 
Sepharose column purification failed to separate both fragments and thus another method 
was used to purify the insert. After enzymatic restriction of the BAC, the DNA sample was 
loaded in several contiguous wells and a PFGE was run. After 14 h of PFGE, gel was stopped 
and wells were excised vertically in two pieces. The first piece containing the marker and one 
well with sample was post-stained with Ethidium Bromide. The band pattern was used as a 
guide to excise the 110 kb fragment from the PFGE gel and later post-stained to confirm the 
correct band excision (Figure 3.14B). DNA sample was eluted from the agarose block, 
concentrated and dialyzed as described before. An aliquot was run in a PFGE to confirm the 
integrity of the 110 kb fragment, as shown in Figure 3.14C. 
 
 
 
 
 
 
 
 
 
 
 
 Figure 3.14 BAC purification for DNA microinjection. (A) PFGE of purified fractions from H3f3b-RFP-ERT2 BAC (B) PFGE of H3f3a-GFP-ERT2 
BAC fragments after PmeI restriction (C) PFGE of H3f3a-GFP-ERT2 fragment after dialysis. 
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The purified DNA samples of H3f3a-GFP-ERT2 and H3f3b-RFP-ERT2 were provided to the 
Transgenic Service of the DKFZ for DNA microinjection into zygotes. 
4.2.3. Identification of chimeras and germ line transmission of H3f3b-RFP-
ERT2 
Genotyping of the offspring from the females implanted with the microinjected zygotes was 
performed by PCR analysis to identify chimeras carrying the over-expression constructs 
(Figure 3.15A and B). 5 chimeras for H3f3a-GFP-ERT2 were identified and 10 for H3f3b-RFP-
ERT2. Chimeras were breed with C57BL/6J wildtype animals to identify founders that 
achieved germ line transmission. One founder for H3f3b-RFP-ERT2 was identified (Litter B, 
Figure 3.15C) and used to expand the mouse line. 
 
 
 
 
 
 
 
 
 
 
Figure 3.15 Genotyping analysis for identification of founders.  (A) Genotyping results for H3f3a-GFP-ERT2 identified 5 potential founders. 
(B) Genotyping results for H3f3b-RFP-ERT2 identified 10 potential founders. (C) Genotyping results comparing one litter that achieved germ 
line transmission (litter B) with one litter that did not achieve it.
B C 
A 
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5. Discussion  
The DIPG field has experienced an outbreak during the last 5 years with several groups 
adding a significant amount of data to a field that did not see much improvement for the 
previous 40 years. This input of new data has shed some light about the mechanism of 
action of the H3.3K27M mutation in these tumors, but has also brought new questions into 
the field. One of the significant aspects of the field is the lack of a proper model to study 
DIPG and be able to use it as a platform for treatment studies. 
 
In order to solve this issue, we intended to develop a mouse model for DIPG adapting our 
established High Grade Glioma model. We designed the H3.3 and H3.3K27M constructs with 
the following features: we tagged them with GFP to be able to identify the tumor cells 
carrying our constructs and also with the intention of separating it from the endogenous 
histone H3.3 in case of further analysis (immunoprecipitation, ChIP-Seq, etc). The sequence 
cloned into the RCAS vector was floxed to permit us to delete the constructs upon tamoxifen 
injection. The goal was to develop HGGs carrying the mutant K27M and whenever fully 
established, delete the mutant histone. By doing this, we would be able to test two main 
things: first, the role of the K27M mutation in the maintenance of the tumor and second, to 
assess the feasibility of K27M as a target for therapy. We designed two constructs, one with 
a mutant H3.3K27M and one with a wildtype H3.3 to be used as a control. Since our model is 
based on over-expression of H3.3K27M, we consider appropriate to include two different 
control groups: one without the mutant histone in which over-expression of AKT and PDGFB 
induced the tumor formation and a second one, consisting of the overexpression of a 
wildtype H3.3 in combination with AKT and PDGFB to assess de possible impact of having an 
extra histone H3.3 gene. 
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We successfully integrated these two constructs in our tumor model which resembled HGG. 
We could observe pathological features mainly present in GBM like pseudopalysading 
necrosis, high proliferation and active angiogenesis. Due to the addition of the RCAS-
luciferase construct, in vivo tumor growth monitoring was possible by BLI. Our tumor model 
reproducibly expressed tagged H3.3/H3.3K27M, however a certain degree of penetrance 
was observed for this trait. A small subset of the tumors displayed what looked like different 
compartments in which GFP and non-GFP cells have separated spatial locations, but most of 
the tumors that displayed a significant amount of non-GFP cells within the tumor region 
showed coexistence of both GFP and non-GFP cells. One possibility to explain this 
phenomenon would be the fact that our tumor model gives rise to tumors coming from 
more than one clone. Given the fact that our survival data doesn’t show a significant 
difference between the GFP, H3.3 and K27M group, one could expect that two clones with a 
different set of mutations might coexist without one overgrowing the other. For example, a 
H3.3 group tumor could arise from two different clones: clone A over-expressing AKT and 
PDGFB would show no GFP expression while clone B over-expressing AKT, PDGFB and H3.3-
GFP would show GFP expression. Another possible explanation would be that some tumor 
cells switch-off the expression of the GFP-expressing constructs giving rise to what would 
look like multi-clonal tumors. To further assess this, genotyping of DNA from a GFP-
expressing tumor region versus a non-GFP-expressing tumor region could be done to 
confirm the presence of the tagged construct DNA in the cells. 
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In order to better mimic the DIPG in our model, we tried to adjust our tumor induction 
location from the SVZ to the pons where DIPG are found in patients. We could successfully 
target the pons in newborn pups but the tumors arising from it using our model did not 
show HGGs features. The tumor region was mainly restricted to the dorsal pons and the 
tumor area was small. Hydrocephaly was predominant in the animals with frequent blood 
clots present in the area between the pons and the cerebellum, usually of considerable size 
even covering the cerebellum completely. Despite the fact of a reduction in the number of 
cells injected in the pons (20000 cells per construct versus 40000 cells per construct for the 
SVZ injection) animals seems to die too early due to the hydrocephaly before the tumors 
could be fully established. Given the aggressiveness of our tumor model, rapid tumor growth 
within the pons is the most likely cause of hydrocephaly by blockage of the CSF flow in the 
ventricles. One possible improvement of the model to be able to adapt to the pons location 
would be eliminating the injection of the AKT oncogene. Previous data in our lab has shown 
that PDGFB over-expression alone is able to induce tumors in which animals displayed a 
significant higher mean survival. A less aggressive tumor approach in the pons may lead to a 
better histological display as well as the possibility of the K27M mutant making a higher 
impact in survival than in our current model. A recent study (Mohammad et al., 2017), 
showed a DIPG mouse model in which mouse NSCs expressing PDGFB and K27M were 
injected in the pons and developed tumors displaying worse survival than NSCs expressing 
PDGFB and wildtype H3.3. This data supports the idea that the combination of PDGFB and 
AKT might be tumorigenic enough such that K27M addition would not make a difference. 
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Our tumor model for DIPG showed that K27M over-expression significantly reduced 
H3K27me3 levels in the tumors compared to the control groups. Furthermore, tamoxifen-
mediated deletion of K27M rescued the H3K27me3 levels. The increase of H3K27me3 ratio 
in K27M cre- tumors, when counting total cells, is probably due to the presence of non-
tumor cells within the tumor and as mentioned before, because of some tumors presenting 
a mixture of GFP and non-GFP cells. This also explains the higher standard deviation for this 
group, accounting for the different ratio of GFP vs non-GFP cells in a particular tumor. 
Despite all of this, differences were still highly significant between the K27M cre- group and 
the other groups. 
As discussed before, there was no significant survival difference among the groups. K27M 
group was close to have significant survival difference with the H3.3 group which could more 
pronounced in the case of a model without AKT over-expression as already discussed. 
Survival analysis of each group cre- and cre+ subgroups did not show significant differences. 
That might lead to the possibility that deletion of K27M does not improve the survival of the 
tumors. However, taking into consideration that AKT and PDGFB over-expression group 
survival did not differ much from AKT, PDGFB and K27M over-expression group survival is 
difficult to discard the possibility that K27M deletion did not alter survival because of the 
aggressiveness of the control group. 
 In conclusion, we developed a robust tumor model for DIPG which allows the tracing and 
inducible deletion of the H3.3K27M in a HGG background. 
Following a similar pattern like its role in gliomagenesis, the study of H3.3 role in the brain is 
a rapidly growing field. Over the last years several studies have linked H3.3 with important 
brain functions such as contextual fear memory but more importantly the discovery of H3.3 
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accumulation in the brain over age points at a greater involvement of H3.3 in a variety of 
brain functions. To contribute in this search we planned to establish tools to study H3.3 
function in the brain. Histone tracing in living behaving animals was intended to be achieved 
making use of an inducible tagged histone H3.3 mouse line. H3.3 is encoded by two different 
genes H3f3a and H3f3b; therefore two mouse lines were designed. BACs were used to over-
express H3f3a and H3f3b to ensure that the modified H3.3 genes would be under the normal 
regulation and promoter influence. BAC clones were modified to tag H3f3a with GFP and 
ERT2 while H3f3b was tagged with RFP and ERT2. The use of GFP and RFP would allow us to 
trace the histone activity in the brain and the use of two different fluorochromes allowed 
the future combination of both mouse lines. The addition of ERT2 will maintain the fusion 
protein in the cytoplasm until tamoxifen would be injected releasing the tagged histone to 
go into the nucleus. With these fusion proteins we would achieve an inducible expression of 
a tagged H3.3. Using these tools, we would be able to monitor H3.3 activity in a inducible 
way in the brain under different activities and if combined with different cre lines in a 
specific cell subtype. We successfully modified H3f3a and H3f3b BAC and used them to 
microinject zygotes. The resulting chimeras for H3f3a-GFP-ERT2 did not achieve germ line 
transmission but a founder for H3f3b-RFP-ERT2 was identified and used to establish the 
mouse line. To further continue with this project, H3f3a-GFP-ERT2 injection could be 
repeated to accomplish germ line transmission. In addition, H3f3b-RFP-ERT2 mouse line will 
require more validation. Southern Blot to analyze the copy number integration and 
tamoxifen injection to confirm the translocation into the nucleus would need to be done 
before conducting more experiments. 
In conclusion, we developed a powerful tool to study H3.3 function in the brain. Additionally, 
the knowledge resulting from the study of H3.3 function in the brain would impact the 
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knowledge about H3.3 role in gliomagenesis and vice versa bringing together the results 
derived from the tools developed in both projects. 
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